SANCY A. LEACHMAN, MD, PhD
CURRICULUM VITAE

Personal Mission Statement: In the pursuit of a healthier world, I will leverage my unique skills and experiences to advance medicine through innovative and collaborative research, education, and health care delivery.

PRESENT POSITION & ADDRESS:

Professor and Chairwoman, Department of Dermatology
John D. Gray Endowed Chair in Melanoma Research
Director, Knight Cancer Institute Melanoma & Skin Cancer Program
Oregon Health & Science University
3303 S Bond Avenue
Portland, OR 97239
Phone: 801-301-1423
Email: leachmas@ohsu.edu

EDUCATION:

Certification

1997	Board Certified, Dermatology

Postgraduate

1996 - 1998	Fellow in Cutaneous Oncology, Yale School of Medicine
1994 - 1997	Resident in Dermatology, Yale New Haven Hospital
1993 - 1994	Intern, Internal Medicine, UT Southwestern Medical School

Undergraduate and Graduate

1985 - 1993	M.D., Ph.D	UT Southwestern Medical School, Dallas, TX
1982 - 1985	B.A.	Plan II Liberal Arts Honors Program, University of Texas at Austin

LICENSURE:

Federal DEA #: BL5403807 Expiration: 03/31/2024
Oregon Medical License #: MD162207 Expiration: 12/31/2021
Texas Medical License #: J6543 Expiration: 05/31/2023
Utah Medical License #: 360389-1205 Expiration: 01/31/2022
Utah Controlled Substance License #: 360389-8905 Expiration: 01/31/2022
Utah DEA license number: FL4226228; Active, exp. 01/31/22
Florida Telemedicine License/Privileges License #: 934 Expiration: N/A

PROFESSIONAL EXPERIENCE:

Academic

2013 - present Attending Physician of Dermatology, Department of Dermatology
Oregon Health & Science University

2013 - present Professor of Dermatology, Department of Dermatology
Oregon Health & Science University

2013 – present Attending Physician, Dermatology
Portland VA & Medical Center

2013 - present Adjunct Professor of Dermatology, Department of Dermatology
University of Utah

2011 - 2013 Professor of Dermatology, Department of Dermatology
University of Utah

2006 - 2011 Associate Professor of Dermatology, Department of Dermatology
University of Utah

1998 - 2013 Attending Physician in Dermatology, Department of Dermatology
University of Utah

1998 - 2006 Assistant Professor of Dermatology, Department of Dermatology
University of Utah

1998 - 2000 Fellow-to-Faculty Transition Program through Molecular Genetics
NIH Training Program, Internal Medicine, University of Utah

Administrative

2013 - present Chair, Department of Dermatology
Oregon Health & Science University

2013 - present Director, Knight Cancer Institute Melanoma and Skin Cancer Program
Oregon Health & Science University

2007 - 2013 Director, Melanoma and Cutaneous Oncology Program
Huntsman Cancer Institute, University of Utah

2004 - 2007 Deputy Director, Melanoma and Cutaneous Oncology
Huntsman Cancer Institute, University of Utah

2003 - 2007 Co-leader, Melanoma and Cutaneous Oncology Program
Huntsman Cancer Institute, University of Utah

2000 - 2013 Director and Principal Investigator
Tom C. Matthews Endowed Familial Melanoma Research Program
Huntsman Cancer Institute, University of Utah

Other

2006 – 2013 Dermatology Clinic Medical Director, Redstone Clinic, Park City
University of Utah

1997 - 1998 Clinical Dermatologist
Michael Friedman and Associates, Stanford, CT

1997 - 1998 Clinical Dermatologist
Yale Health Plan, New Haven, CT

Honors

2021 Career Achievement Award & Aaron Lerner Lectureship
Pan American Society for Pigment Cell Research

2019 OHSU Dermatology Teacher of the Year

2018 – present John D. Gray Endowed Chair in Melanoma Research
Oregon Health & Science University

2017 – 2021 Portland Monthly, Top Doctor

2016 Estela Medrano Memorial Award

2003 – 2021 Dermatology Castle Connolly Top Doctor Since 2003

2001 – 2013 Tom C. Mathews Jr. Familial Melanoma Research Endowment

2000 – 2004 Doris Duke Clinical Scientist Development Award

LEADERSHIP:

Dr. Leachman's leadership philosophy emphasizes collaboration, innovation, and empowerment, utilizing a situational leadership style, tailored to meet the diverse needs and approaches of the people with whom she works. Dr. Leachman's primary leadership roles have been as Director of the Melanoma & Cutaneous Oncology Program at Huntsman Cancer Institute at the University of Utah, Director of the Melanoma and Skin Cancer Program at Knight Cancer Institute at Oregon Health & Science University (OHSU), and Department Chair of Dermatology at OHSU. She has also been a leader in the Faculty Practice Plan and the School of Medicine at OHSU and in dermatologic and melanoma organizations nationally and internationally.

Huntsman Cancer Institute at University of Utah. Dr. Leachman was successfully recruited to the University of Utah in 2000 to bring multiple disciplines together and help build the world-class, translational Melanoma Program that she envisioned. She was promoted to Deputy Director of the Melanoma Program in 2004, and then promoted to Director in 2007, serving as Director until 2013. As

Director, Dr. Leachman built the program from a single medical oncologist, single surgical oncologist, and two dermatologists to one of the strongest melanoma programs in the country. Harnessing Utah's institutional strength in human genetics, she built a world-class Familial Melanoma Program, which attracted an enduring endowment for the Tom C. Mathews Familial Melanoma Clinic.

Knight Cancer Institute Melanoma & Skin Cancer Program. In 2013 Dr. Leachman was selected as the leader of OHSU's new Melanoma & Skin Cancer Program at Knight Cancer Institute because of her track record of collaboration with and leadership of faculty from diverse departments and specialties. Dr. Leachman received the $2.5M John D. Gray Endowment for Melanoma Research and another $2.5M to support the program development. She built the Melanoma Program from a base of one surgical oncologist and one medical oncologist and created a statewide public health and population science program in melanoma early detection called the War On Melanoma™. This strategy increased visibility and accessibility to patients across the state, filled surgical and medical oncology pipelines, and created clinical trial opportunities. The Melanoma Program at OHSU currently consists of five medical dermatologists, two dermatopathologists, a surgical pathologist, a radiation oncologist, an ocular oncologist, two surgical oncologists, two medical oncologists, a medical geneticist, a nuclear medicine physician, and five basic scientists.

OHSU Department of Dermatology. Dr. Leachman has partnered closely with OHSU leadership and faculty to transform the structure and culture of the Department of Dermatology, based on a set of core values. As the first female clinical chair at OHSU she focused on a culture of excellence, applied Lean principles (OHSU OpEx), and built a "Team of Teams" organizational structure under the Stanley McCrystal model. She focused on recruitment of diverse and talented faculty, managers and staff. Dr. Leachman has doubled the number of faculty and employees in the department, including the recruitment of 25 faculty from across the United States and Europe, making the Department one of the largest and most diverse in the country (now 43 faculty and almost 150 non-faculty employees). Under her leadership, the residency program has become one of the most competitive in the country and three new ACGME fellowship programs have been accredited (Mohs Surgery & Procedural Dermatology, Pediatric Dermatology, and Dermatopathology). During her tenure as Chair, a departmental Clinical Trials Unit and Dermatopathology Laboratory have been established and are flourishing.

Oregon Health & Science University. To contribute toward and capitalize on the major strengths of OHSU, Dr. Leachman has aligned her departmental vision with that of the greater institution. This required participation in critical committees and institutional administrative structures. Dr. Leachman has served on a number of leadership teams at OHSU including the Pro Board and the Hospital Management Committee. She is one of two chairs on the Finance Council working directly with the Dean and CEO of the OHSU Health System, and was recently appointed as the chair representative to lead the new Funds Flow Committee. She has been recruited by the Dean and Hospital CEO to be one of five Chairs in their Clinical Leadership Council. Dr. Leachman has also introduced telehealth into the department, and Dermatology now leads the institution in the number of virtual visits, e-visits, and e-consults. During her tenure as chair, Dr. Leachman has created innovative compensation plans and expanded the departmental budget from $18M to $26M in an era of financial uncertainty and a global pandemic.

Leadership & Influence on the Fields of Melanoma and Dermatology. Dr. Leachman's sphere of influence extends beyond institutional boundaries. She is the Co-Chair of the Melanoma Prevention Working Group, a joint working group of the Southwest, Eastern, and CALGB NCI-sponsored Oncology Groups, and hub of

the Pigmented Lesion Subcommittee through the American Academy of Dermatology. She is currently the Chair of the American Academy of Dermatology's Melanoma/Skin Cancer Community Programs Committee and has been on several scientific advisory boards, including the Society for Melanoma Research and the Pan American Society for Pigment Cell Research.

SCHOLARSHIP:

Dr. Leachman's career has been devoted to the application of science to medicine, particularly molecular genetics. As a dermatologist, her focus has been on human genetic skin disorders and melanoma. Over the past 23 years as a faculty member in the academic community, she has incorporated methods and tools across basic and clinical science, population science, public health, and behavioral health to create innovative trans- and multi-disciplinary approaches to prevention, detection, and treatment of disease.

Cohort development. Strong clinical investigation requires a patient cohort with controls. Dr. Leachman has built two large and unique melanoma cohorts, and a worldwide cohort of patients with pachyonychia congenita, a genetic keratin disorder.

- The Utah melanoma cohort contains over 1,800 hereditary melanoma family members (affected and unaffected), assembled through collaboration with the Utah Population Database and the Utah Cancer Registry.
- The Oregon melanoma cohort, AKA the Melanoma Community Registry (an IRB-approved repository, https://www.ohsu.edu/war-on-melanoma/melanoma-community-registry), contains >10,000 primarily sporadic melanoma patients, family members and controls. This cohort was recruited through collaboration with the Oregon State Cancer Registry and with a unique mobile iPhone application (MoleMapper) that Dr. Leachman developed in-house through collaboration with software engineers.
- Dr. Leachman also created a pachyonychia congenita cohort by co-founding PC Project, a patient advocacy organization, where the patient registry still remains the largest and most utilized resource for investigation of this disease.
- These cohorts are associated with personal and family history, physical examination, and other retrievable annotation; they are tracked longitudinally, and participants receive regular communications. These cohorts have become a resource that has supported numerous basic and clinical research projects, publications, grants, and clinical trials led by Dr. Leachman and others.

Basic science research. Dr. Leachman has directed a Foundation and NIH-funded basic science and translational laboratory since 2002. Her basic science research program has focused on three main areas: genetic epidemiology, molecularly targeted melanoma chemoprevention, and molecular prognostics/therapeutics.

- Dr. Leachman was NIH R01 funded to identify novel melanoma predisposition genes in her Utah cohort. She and her collaborators were the first to report novel mutations in GOLM1 and OCA2 in hereditary melanoma.
- She and her collaborators were also the first to report on the role of CDKN2A/p16, the major melanoma predisposition gene, in the oxidative stress pathway in melanocytes and among the first to elucidate the importance of MC1R and pigmentation in cellular protection against UV and oxidative damage. These discoveries, supported by competitive internal and external NIH R01,

R03, and R21 funding have identified a new targetable pathway in the high-risk melanoma population. Dr. Leachman has moved forward with these discoveries to systematically test a pipeline of anti-oxidant agents in vitro (selenium, N-acetyl cysteine, sulforaphane, piperine and nicotinamide) as candidate chemoprevention agents in melanoma.

- Dr. Leachman was also funded by PC Project to develop a potent single-nucleotide-specific siRNA to target a dominant-negative keratin 6a mutation and test it in an in vitro and mouse skin model. This siRNA agent ultimately advanced to a first-in-man Phase I clinical trial led by Dr. Leachman.

Translational research. Dr. Leachman has utilized data and samples from her research cohorts for a wide variety of translational studies. These studies include identification and testing of molecular markers of response to therapy, global expression profiling and genomic analysis of cultured human melanocytic cells, immunohistochemical analyses of human tissues for biomarkers, and validation of findings from pre-clinical mouse trials (chemoprevention agents) in humans. In addition to the Melanoma Community Registry resource, the Department of Dermatology and Knight Cancer Institute have formal clinical trial units and dermatopathology and molecular pathology CAP-certified (and CLIA-certified) laboratories that provide translational research support to her group. In addition, Dr. Leachman has led the first and is currently leading an update on the International Melanoma Genetics Consortium's (GenoMEL) consensus guidelines on melanoma genetic testing. She chairs the American Academy of Dermatology's Melanoma Committee, which is pushing forward a stratified skin cancer screening program based on risk data. Dr. Leachman co-chairs the Melanoma Prevention Working Group, a joint program between the Southwest Oncology, Eastern Oncology, and CALGB NCI Cooperative Groups, which serves as the major melanoma prevention working group in the USA.

Clinical research. Dr. Leachman has a track-record of moving molecular agents into clinical trials as well as directing industry-sponsored trials in melanoma. She was able to move a single nucleotide siRNA from discovery, through pre-clinical animal studies, through the FDA IND-approval process, and into a successful investigator-initiated Phase I clinical trial for pachyonychia congenita. Although the agent has not moved forward due to delivery obstacles (intralesional injection was poorly tolerated in this condition), the agent remains available for re-evaluation in a topical formulation. She and her colleagues also obtained IND permission to test N-acetylcysteine, one of the candidate chemoprevention agents in their pipeline, in high-risk patients. She was also site PI of the first prospective chemoprevention trial for melanoma using lovastatin. Her lab is poised at this time to move two additional chemoprevention candidates for melanoma into early-phase clinical trials and also to ultimately test any successful agent in her high-risk melanoma cohort. Dr. Leachman has also worked with Castle Biosciences, Merck, Myriad Genetic Laboratories, Orlucent, Inc., Sklip, Inc., and DermDetect, Inc. to investigate molecular and imaging technologies for melanoma in clinical studies and trials.

Population science and public health (Oregon's War on Melanoma™). Upon Knight Cancer Institute's successful billion-dollar fundraising challenge for early detection of cancer in 2015, Dr. Leachman launched the Melanoma and Skin Cancer Program's War on Melanoma™. The War on Melanoma™ is a statewide public health program designed to improve early detection of melanoma through stratified education and screening (www.WarOnMelanoma.org). Full-spectrum community outreach and education occurs in the lay population (with an emphasis on rural communities), the licensed skin services community, the primary care provider community, and the dermatology and multidisciplinary melanoma provider community. The Oregon cohort (Melanoma Community Registry) provides a foundation for this patient-centered project, supplemented by collaboration with the Oregon State Medical Board for access to licensed skin-care professionals and providers. Outreach to the lay population includes online

education (www.StartSeeingMelanoma.com); social media, billboard, and e-mail campaigns; radio and TV public service announcements; recommendation of MoleMapper, an iPhone mole-tracking application developed at OHSU; and e-visit access to OHSU dermatologists. Outreach to primary care providers includes an online educational toolkit with continuing medical education opportunities; virtual dermoscopy training roundtable; risk assessment tools for clinic; educational materials for their patients; and e-consult services with OHSU dermatology. Resources for melanoma experts include access to Dermatology's new Skin Imaging and Technology Center with access to digital sequential dermoscopy and total body imaging services, in vivo confocal microscopy services, and access to virtual multidisciplinary tumor board review. Use and effectiveness metrics have been established for most of these interventions in order to assess value of the program components relative to melanoma incidence, prognosis, and mortality rates.

Technology and innovation. The use of technology can dramatically improve early detection of melanoma in low-access and rural areas as well as improve detection at the earliest stages of the disease. Developed by Dr. Leachman's team, MoleMapper™ is a cellphone app available in Apple®'s App Store. Part of the ResearchKit suite of apps, MoleMapper™ facilitates data collection for melanoma research and, potentially, impacts health outcomes in individuals at risk for melanoma. MoleMapper™ tracks moles and how they change and grow over time. MoleMapper™ also reminds users to re-check moles regularly. By sharing mole images over time, researchers can develop new ways of evaluating moles and may be able to tell whether the user should see a doctor or have a mole removed based on a cell phone picture. The images collected in this crowdsourced way may ultimately fuel our artificial intelligence program that will permit automated screening, at least for triage purposes. In addition to MoleMapper™, Dr. Leachman has launched a Skin Imaging and Technology Center that is facilitating home dermoscopy and PCP-provided consultative dermoscopy with Sklip™. The Center offers clinical in vivo reflectance confocal microscopy to avoid unnecessary biopsies and detect the earliest changes and borders of melanoma without a traditional biopsy. Dr. Leachman has introduced digital pathology into the department as well as molecular diagnostic and prognostic tools. The Imaging Center photonics and engineering research faculty are collaborating with investigators in ophthalmology to transform ocular optical coherence tomography into a skin device. They are also participating in clinical trials to test gene expression profiling, tape stripping, fluorescent dermoscopy, and other methods for melanoma early detection.

Behavioral and social psychology research. Dr. Leachman's work with genetically predisposed populations revealed that knowledge and understanding of their high-risk status was insufficient to precipitate change in prevention behaviors such as photo-protection, skin self-exam, or compliance with recommended provider skin exams. Our group was the first to demonstrate that genetic test reporting in a high-risk cohort increases compliance with prevention recommendations. Dr. Leachman and colleagues' work has focused on better understanding of the cognitive "switch" that leads to increased compliance. She and colleagues have also worked with high-risk families to investigate how education and mutation testing impacts children. These ongoing behavioral studies bridge the gap between molecular genetic technologies (mutations that predict risk) and implementation of behavioral changes that are necessary to reduce disease.

GRANTS & CONTRACTS:

Federal Active

6/01/15 - 11/30/22 5 R13 AR009431-55
Montagna Symposium on the Biology of Skin
Principal Investigator: Sancy A. Leachman
Direct Costs: $40,000 Total Costs: $40,000
NIH NIAMS, NIA
Role: Principal Investigator (10% effort)

Federal Pending

TBD, 1.5 years R44 CA1019914
AIRISE (In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response)
Principal Investigator: Wassana Yantasee
Total Costs: $2.5 milion
PDX Pharma (NIH NCI)
Role: Consultant

Federal Previous

8/10/18 - 7/31/19 1 R13 AR074279-01
2018 PASPCR Annual Meeting: "Melanoma to Vitiligo: The Melanocyte in Biology & Medicine"
Principal Investigator: Sancy A. Leachman
Direct Costs: $18,000 Total Costs: $18,000
NIH NIAMS, NIEHS
Role: Principal Investigator

04/08/11 - 03/31/18 R01 CA158322
Impact of Melanoma Genetic Testing on Health Cognitions and Prevention Behaviors
Principal Investigators: Lisa G. Aspinwall and Sancy A. Leachman
Direct Costs: $818,123 Total Costs: $1,222,443
NIH NCI
Role: Principal Investigator (10% effort)

07/01/16 - 06/20/17 Developing Infrastructure for Patient-Centered Melanoma Research II
Principal Investigator: Sancy A. Leachman
Direct Costs: $7,150.00 Total Costs: $7,865.00
Sub award from Colorado Foundation for Public Health & the Environment / PCORI
Role: Principal Investigator (.9 % effort)

07/01/15 - 03/31/16 Developing Infrastructure for Patient-Centered Melanoma Research
Principal Investigator: Sancy A. Leachman
Direct Costs: $7,150.00 Total Costs: $7,865.00

Sub award from Colorado Foundation for Public Health & the Environment / PCORI
Role: Principal Investigator (.9 % effort)

02/01/14 - 01/31/16 R21 CA183440
How p16 and MC1R Mutations Synergistically Exacerbate Melanoma Risk
Principal Investigators: Zalfa Abdel-Malek and Sancy A. Leachman
Annual Direct Costs: $162,799
Sub award from University of Cincinnati / NIH NCI
Role: Principal Investigator (5% effort)

07/01/09 - 06/30/14 R01 ES017561
Impact of MC1R Functional Variants on the DNA Damage Response of Human Melanocytes
Principal Investigator: Zalfa Abdel-Malek and Sancy A. Leachman
Direct Costs: $50,306 Total Costs: $75,711
Sub award from University of Cincinnati / NIH NIEHS
Role: Co-Principal Investigator

08/01/12 - 03/31/13 R13 AR063595
17th Annual Meeting of the Pan American Society of Pigment Cell Research
Principal Investigator: Sancy A. Leachman
Direct Costs: $25,000 Total Costs: $25,000
NIH NIAMS
Role: Principal Investigator

11/01/10 - 04/29/11 HHSN261200433000C/N01 CN43300
Human Melanoma: Early Biomarkers/Targets of Progression and Prevention
Principal Investigator: Keith Crist
NCI subproject N201143
Principal Investigator: Sancy A. Leachman
Direct Costs: $136,863 Total Costs: $205,979
Sub award from the University of Toledo / NIH NCI
Role: Principal Investigator

09/27/10 - 10/26/12 W81XWH-10-2-0185
Molecular Determinants of Melanoma Susceptibility and Progression
Direct Costs: $240,997 Total Costs: $362,700
U.S. Department of Defense
Role: Co- Principal Investigator

09/03/06 - 09/29/09 Lovastatin Melanoma Pathobiology
Principal Investigators: Frank Meyskens and Wolfram E. Samlowski
Direct Costs: $264,773 Total Costs: $363,067
University of California, Irvine / NIH NCI
Role: Sub-Recipient Principal Investigator

09/20/08 - 09/19/09 PC Independent Study
Principal Investigator: Sancy A. Leachman
Direct Costs: $136,667 Total Costs: $176,235
NIH NCRR
Role: Principal Investigator

09/01/06 - 08/01/08 R03 CA125854
A New Method for Delivery of Selenium for Prevention of Melanoma
Principal Investigator: Pamela Cassidy
NIH NCI
Role: Collaborator

09/01/03 - 08/01/08 R01 CA102422
Identification of Melanoma Predisposition Loci
Principal Investigator: Lisa Cannon-Albright
NIH NCI
Role: Co-Investigator

09/01/06 - 08/01/08 R03 CA125761
Oxidative Stress and Melanoma Chemoprevention
Principal Investigator: Douglas Grossman
NIH NCI
Role: Collaborator

06/01/05 - 06/01/06 Behavioral Aspects of Melanoma Patients Undergoing Care
Principal Investigator: Lisa Aspinwall
National Institutes of Health
Role: Collaborator

01/01/02 - 12/01/04 Post-translational Modifications of DNA Damage Response Proteins as a Measure of Cellular Response to Low Doses of Ionizing RD
Ray Warters
US Department of Energy
Role: Collaborator

State and Local Active

State and Local Previous

12/01/18 - 12/14/20 CEDAR Seed Grant
War on Melanoma Early Detection Public Health Research Study
Principal Investigator: Sancy Leachman
Direct Costs: $140,250
OHSU Knight Cancer Institute
Role: Principal Investigator (2.5% effort)

05/01/14 - 12/31/15 2014-Knight Pilot-05
War on Melanoma

Principal Investigators: Sancy Leachman and Jackilen Shannon
Direct Costs: $50,000
OHSU Knight Cancer Institute
Role: Principal Investigator (0% effort)

09/01/11 - 08/31/12 UCAN Sponsorship
Principal Investigator: Sancy A. Leachman
Direct Costs: $1,000 Total Costs: $1,000
Utah Cancer Action Network
Role: Principal Investigator

07/01/10 - 06/30/11 The SCOPE Project: Skin Cancer Outdoor Prevention Education
Principal Investigator: Jeffrey Paul Yancey
Direct Costs: $4,552 Total Costs: $4,552
Utah Cancer Action Network
Role: Co-Investigator

06/01/05 - 05/01/06 A Prospective Longitudinal Study of Psychological and Behavior Responses to the Receipt of *p16* Genetic Testing Results
Principal Investigator: Sancy A. Leachman
University of Utah
Role: Co-Principal Investigator

07/01/99 - 06/30/00 Systematic Identification of Genes Regulating Papillomavirus-Induced Transformation. Funding Incentive Seed Grant Program.
Principal Investigator: Sancy A. Leachman
Direct Costs: $34,000 Total Costs: $34,000
University of Utah Research Foundation
Role: Principal Investigator

Other Support Active

01/01/19 - 12/31/21 Melanoma Tissue Bank Consortium (MTBC)
Principal Investigator: Sancy A. Leachman
Direct Costs: $334,750 Total Costs: $418,438
AIM at Melanoma Foundation
Role: Principal Investigator (10% effort)

Other Support Previous

02/18/15 - 12/31/20 Translational Studies of Piperine for Vitiligo
Principal Investigator: Sancy A. Leachman
Total Costs: $125,000
Niramaya, LLC
Role: Principal Investigator (0% effort)

05/01/10 - 09/30/13 Scibase International Melanoma
Direct Costs: $33,422 Total Costs: $44,352

Scibase International
Role: Co-Investigator
Familial Melanoma Research (endowment)

07/01/01 - 6/30/13 Tom C. Mathews Jr. Foundation
Principal Investigator: Sancy A. Leachman
Huntsman Cancer Institute
Role: Principal Investigator

06/01/09 - 05/31/11 Sulforaphane and Melanoma
Principal Investigator: Sancy A. Leachman
Direct Costs: $100,000 Total Costs: $100,000
Melanoma Research Foundation
Role: Principal Investigator

06/01/09 - 05/31/11 De-Mystify Hereditary Melanoma
Principal Investigator: Sancy A. Leachman
Direct Costs: $34,750 Total Costs: $34,750
American Academy of Dermatology
Role: Principal Investigator

12/01/05 - 11/30/10 Genetic and Environmental Determinants of Melanoma
Principal Investigator(s): Lisa A. Cannon-Albright and Sancy A. Leachman
Direct Costs: $205,320 Total Costs: $246,384
European Commission
Role: Principal Investigator

12/29/05 - 09/30/06 Dermtech - Tape Stripping
Principal Investigator: Sancy A. Leachman
Direct Costs: $5,412 Total Costs: $6,900
DermTech International
Role: Principal Investigator

07/01/05 - 06/30/06 Detection and Characterization of Premalignant Transformation of Melanoma.
Technology Commerce Program. Cost Reimbursable.
Principal Investigator: Sancy A. Leachman
Direct Costs: $70,000 Total Costs: $70,000
Dermatology Foundation
Role: Principal Investigator

07/01/04 - 06/30/05 Elucidation of the Role of the Melanocortin 1 Receptor Gene as a Melanoma Susceptibility Gene. Cost Reimbursable.
Principal Investigator: Sancy A. Leachman
Direct Costs: $20,000 Total Costs: $20,000
Dermatology Foundation
Role: Principal Investigator

07/01/00 - 06/30/04 Familial Melanoma
Principal Investigator: Sancy A. Leachman
Direct Costs: $500,000 Total Costs: $500,000
Doris Duke Charitable Foundation (DDCF)
Role: Principal Investigator

07/01/00 - 06/30/03 Identification of Molecular Pathways Regulating Papillomavirus-Induced Transformation. Cost Reimbursable. Closed11-6-00.
Principal Investigator: Sancy A. Leachman
Direct Costs: $55,000 Total Costs: $55,000
Dermatology Foundation
Role: Principal Investigator

04/01/00 - 11/01/02 Basic Science Phase 1 Trial for Inhibition of DNA Methylation by Continuous Fusion of 5 AZA 2 Deoxycytidine (Decitibine)
Principal Investigator: Sancy A. Leachman
Supergen Inc
Role: Co-Principal Investigator

09/01/98 - 07/01/01 Fellow-to-Faculty Transition Program
Howard Hughes Medical Institute
Role: Trainee

07/01/99 - 04/24/00 Systematic Identification of Genes Regulating Papilloma Virus Induced Transformation. Cost Reimbursable.
Principal Investigator: Sancy A. Leachman
Direct Costs: $25,000 Total Costs: $25,000
Dermatology Foundation
Role: Principal Investigator

1996 - 1998 NIH Training Fellowship
Yale University, Department of Dermatology
Role: Trainee

1985 - 1993 NIH Medical Scientist Training Program, Grant Recipient
University of Texas
Role: Trainee

1985 - 1986 Southwestern Medical Foundation Scholarship
Role: Trainee

Grants as mentor

10/1/21 – 09/30/24 Preventing Metastasis of High Risk Melanoma
Principal Investigator: Wesley Yu
Direct Costs: $300,000
Department of Defense
Role: Mentor (0% FTE)

07/01/21 – 06/30/22 Preventing Metastasis of High Risk Melanoma
Principal Investigator: Wesley Yu
Direct Costs: $165,000
Dermatology Foundation
Role: Mentor (0% FTE)

07/01/21 – 06/30/22 Melanoma Antigen Dispersal Pathways in the Lymph Node: Direct Anti-tumor T Cell Reactivity
Principal Investigator: Megan Ruhland
Direct Costs: $135,000
Harry J. Lloyd Charitable Trust
Role: Mentor (0% FTE)

01/21/21 – 12/31/21 Preventing Metastasis of Genetically High Risk Melanoma
Principal Investigator: Wesley Yu
Direct Costs: $30,000
Collins Medical Trust
Role: Mentor (0% FTE)

07/01/20 – 06/30/22 Multimedia Learning for Melanoma Prevention and Early Detection Education
Principal Investigator: Carter Haag
Direct Costs: $80,000
Melanoma Research Foundation
Role: Mentor (0% FTE)

01/01/20 – 12/31/23 Family-focused melanoma preventive intervention for children of survivors
Principal Investigator: Yelena Wu
Direct Costs: $675,500
American Cancer Society
Role: Mentor (0% FTE)

05/20/20 – 12/20/21 Implementing Evidence-based Primary Prevention Interventions focused on Liver, Cervical, and Skin Cancer in Childhood
Principal Investigator: Rosmaria Frutos, Kerri Lopez
Direct Costs: $50,000
Centers for Disease Control
Role: Collaborator with Northwest Portland Area Indian Health Board – Northwest Tribal Comprehensive Cancer Control Program (0% effort)

05/01/20 – 05/01/21 Applying Cognitive Theory of Multimedia Learning to Melanoma Prevention Education in High School Adolescents
Principal Investigator: Victoria Orfaly
Direct Costs: $3,000
Melanoma Research Foundation
Role: Mentor 0% FTE

05/15/16 – 05/14/19 Lymphatic Vessels and T cell-Inflammation in Melanoma

Principal Investigator: Amanda Lund
Direct Costs: $225,000
Melanoma Research Foundation
Role: Mentor (0% FTE)

09/01/15 – 08/31/19 Melanoma-Associated Lymphangiogenesis, Immune Suppression, and Response to Targeted Therapy
Principal Investigator: Amanda Lund
Direct Costs: $358,850
Department of Defense
Role: Mentor (0% FTE)

08/01/15 – 07/31/20 Translational approaches to melanoma prevention in children at high genetic risk
Principal Investigator: Yelena Wu
Direct Costs: $631,666
NIH / NCI
Role: Mentor (0% FTE)

Mentored Grants (Pending)

10/01/21 – 09/30/24 Targeting dendritic cell programming to boost anti-tumor T cell responses
Principal Investigator: Megan Ruhland
Direct Costs: $180,000
Edward Mallinckrodt, Jr. Foundation
Role: Mentor (0% FTE)

PUBLICATIONS & CREATIVE WORK:

Peer-reviewed

1. Gonzales FR, **Leachman S**, Norgard MV, Radolf JD, McCracken GH Jr, Evans C, Hansen EJ. (1987). Cloning and expression in Escherichia coli of the gene encoding the heat-modifiable major outer membrane protein of Haemophilus influenzae type b. *Infect Immun*, *55*(12), 2993-3000.

2. **Leachman SA**, Gallagher PJ, Herring BP, McPhaul MJ, Stull JT. (1992). Biochemical properties of chimeric skeletal and smooth muscle myosin light chain kinases. *J Biol Chem*, *267*(7), 4930-8.

3. **Leachman SA**, Insogna KL, Katz L, Ellison A, Milstone LM. (1999). Bone densities in patients receiving isotretinoin for cystic acne. *Arch Dermatol*, *135*(8), 961-5.

4. **Leachman SA**, Tigelaar RE, Shlyankevich M, Slade MD, Irwin M, Chang E, Wu TC, Xiao W, Pazhani S, Zelterman D, Brandsma JL. (2000). Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model. *J Virol*, *74*(18), 8700-8.

5. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, **Leachman SA**. (2001). Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. *Mod Pathol*, *14*(2), 116-28.

6. Agarwal-Antal N, Zimmermann J, Scholz T, Noyes RD, **Leachman SA**. (2002). A giant verruciform xanthoma. *J Cutan Pathol*, *29*(2), 119-24.

7. **Leachman SA**, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL. (2002). Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. *J Virol*, *76*(15), 7616-24.

8. Florell SR, Boucher KM, **Leachman SA**, Azmi F, Harris RM, Malone JC, Martignoni G, Bowen GM, Gerwels JW, Hood AF. (2003). Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. *Arch Dermatol*, *139*(5), 595-604.

9. Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, **Leachman SA**. (2003). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. *Pigment Cell Res*, *16*(6), 662-9.

10. Call TR, Boucher KM, Whiting BL, Hart M, Newman K, Kinney AY, Bowen GM, Zone JJ, Branson D, **Leachman SA**. (2004). Motivating factors for attendance of skin cancer screenings. *J Am Acad Dermatol*, *51*(4), 642-4.

11. Herron MD, Vanderhooft SL, Smock K, Zhou H, **Leachman SA**, Coffin C. (2004). Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. *Am J Surg Pathol*, *28*(8), 1017-25.

12. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2004). Longitudinal assessment of the nevus phenotype in a melanoma kindred. *J Invest Dermatol*, *123*(3), 576-82.

13. Pond CD, **Leachman SA**, Warters RL. (2004). Accumulation, activation and interindividual variation of the epidermal TP53 protein in response to ionizing radiation in organ cultured human skin. *Radiat Res*, *161*(6), 739-45.

14. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, **Leachman SA**. (2005). Population-based analysis of prognostic factors and survival in familial melanoma. *J Clin Oncol*, *23*(28), 7168-77.

15. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, **Leachman SA**, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS. (2005). Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. *Cancer*, *104*(8), 1678-86.

16. Samlowski WE, **Leachman SA**, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. (2005). Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. *J Clin Oncol*, *23*(17), 3897-905.

17. Warters RL, Adamson PJ, Pond CD, **Leachman SA**. (2005). Melanoma cells express elevated levels of phosphorylated histone H2AX foci. *J Invest Dermatol*, *124*(4), 807-17.

18. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, **Leachman SA**. (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. *J Invest Dermatol*, *126*(3), 660-6.

19. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, **Leachman SA**, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res*, *66*(20), 9818-28.

20. Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, **Leachman SA**, Grossman D. (2006). Activation of dual apoptotic pathways in human melanocytes and protection by survivin. *J Invest Dermatol*, *126*(10), 2247-56.

21. Wakamatsu K, Kavanagh R, Kadekaro AL, Terzieva S, Sturm RA, **Leachman S**, Abdel-Malek Z, Ito S. (2006). Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin. *Pigment Cell Res*, *19*(2), 154-62.

22. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, **Leachman SA**, Lee RM, Grossman D. (2006). Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. *Oncogene*, *25*(52), 6968-74.

23. Cotter MA, Thomas J, Cassidy P, Robinette K, Jenkins N, Florell SR, **Leachman S**, Samlowski WE, Grossman D. (2007). N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. *Clin Cancer Res*, *13*(19), 5952-8.

24. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, **Leachman SA**. (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. *Arch Dermatol*, *143*(11), 1409-12.

25. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, **Leachman SA**, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet*, *44*(2), 99-106.

26. Larson AA, **Leachman SA**, Eliason MJ, Cannon-Albright LA. (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. *J Invest Dermatol*, *127*(1), 183-8.

27. Liao H, Sayers JM, Wilson NJ, Irvine AD, Mellerio JE, Baselga E, Bayliss SJ, Uliana V, Fimiani M, Lane EB, McLean WH, **Leachman SA**, Smith FJ. (2007). A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. *J Dermatol Sci*, *48*(3), 199-205.

28. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, **Leachman SA**, Boucher KM, Samlowski WE. (2007). Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. *Cancer*, *110*(6), 1329-37.

29. Warters RL, Williams DL, Zhuplatov SB, Pond CD, **Leachman SA**. (2007). Protein phosphorylation in irradiated human melanoma cells. *Radiat Res*, *168*(5), 535-44.

30. Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, **Leachman SA**. (2008). CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. *Cancer Epidemiol Biomarkers Prev*, *17*(6), 1510-9.

31. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, **Leachman SA**. (2008). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. *J Invest Dermatol*, *128*(8), 2122-2125.

32. Florell SR, Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, **Leachman SA**. (2008). Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. *J Am Acad Dermatol*, *59*(5), 814-21.

33. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, **Leachman SA**, Milstone LM, McLean WH, Kaspar RL. (2008). Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. *J Invest Dermatol*, *128*(3), 594-605.

34. Kohlmann W, Dunn K, **Leachman SA**. (2008). Role of genetic testing in hereditary melanoma. *Expet Rev Dermatol*, *3*(6), 639-643.

35. Pershing LK, Tirumala VP, Nelson JL, Corlett JL, Lin AG, Meyer LJ, **Leachman SA**. (2008). Reflectance spectrophotometer: the dermatologists' sphygmomanometer for skin phototyping? *J Invest Dermatol*, *128*(7), 1633-40.

36. Seltzer MH, **Leachman SA**. (2008). Breast cancer and melanoma in the same pedigree. *Dermatol Online J*, *14*(11), 1.

37. Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, **Leachman SA**. (2009). Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. *J Am Acad Dermatol*, *60*(5), 745-57.

38. Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, Gensini F, Gliori S, Guida M, Lombardo M, Manoukian S, Menin C, Nasti S, Origone P, Pasini B, Pastorino L, Peissel B, Pizzichetta MA, Queirolo P, Rodolfo M, Romanini A, Scaini MC, Testori A, Tibiletti MG, Turchetti D, **Leachman SA**, Bianchi Scarra G. (2009). Clinical genetic testing for familial melanoma in Italy: A cooperative study. *J Am Acad Dermatol*, *61*(5), 775-82.

39. Hickerson RP, Leake D, Pho LN, **Leachman SA**, Kaspar RL. (2009). Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. *J Dermatol Sci*, *56*(2), 82-8.

40. **Leachman SA**, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. (2009). Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol*, *61*(4), 677.e1-14.

41. Branstrom R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall LG, Azizi E, Baron-Epel O, Battistuzzi L, Bergman W, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, **Leachman SA**, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y. (2010). Predictors of sun protection behaviors and severe sunburn in an international online study. *Cancer Epidemiol Biomarkers Prev*, *19*(9), 2199-210.

42. **Leachman SA**, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. *Mol Ther*, *18*(2), 442-6.

43. Kadekaro AL, **Leachman S**, Kavanagh RJ, Swope V, Cassidy P, Supp D, Sartor M, Schwemberger S, Babcock G, Wakamatsu K, Ito S, Koshoffer A, Boissy RE, Manga P, Sturm RA, Abdel-Malek ZA. (2010). Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. *FASEB J (Online)*, *24*(10), 3850-60.

44. Leaf SL, Aspinwall LG, **Leachman SA**. (2010). God and agency in the era of molecular medicine: religious beliefs predict sun-protection behaviors following melanoma genetic test reporting. *Archive for the Psychology of Religion (English)*, *32*, 1-26.

45. Taber JM, Aspinwall LG, Kohlmann W, Dow R, **Leachman SA**. (2010). Parental preferences for CDKN2A/p16 testing of minors. *Genet Med*, *12*(12), 823-38.

46. Warters RL, Cassidy PB, Sunseri JA, Parsawar K, Zhuplatov SB, Kramer GF, **Leachman SA**. (2010). The nuclear matrix shell proteome of human epidermis. *J Dermatol Sci*, *58*(2), 113-22.

47. Wilson NJ, Messenger AG, **Leachman SA**, O'Toole EA, Lane EB, McLean WH, Smith FJ. (2010). Keratin K6c mutations cause focal palmoplantar keratoderma. *J Invest Dermatol*, *130*(2), 425-9.

48. Fu T, **Leachman SA**, Wilson NJ, Smith FJ, Schwartz ME, Tang JY. (2011). Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. *J Invest Dermatol*, *131*(5), 1025-8.

49. Garcia M, Larcher F, Hickerson RP, Baselga E, **Leachman SA**, Kaspar RL, Del Rio M. (2011). Development of skin-humanized mouse models of pachyonychia congenita. *J Invest Dermatol*, *131*(5), 1053-60.

50. Hickerson RP, Flores MA, Leake D, Lara MF, Contag CH, **Leachman SA**, Kaspar RL. (2011). Use of Self-Delivery siRNAs to Inhibit Gene Expression in an Organotypic Pachyonychia Congenita Model. *J Invest Dermatol*, *131*(5), 1037-44.

51. Hickerson RP, **Leachman SA**, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL. (2011). Development of quantitative molecular clinical end points for siRNA clinical trials. *J Invest Dermatol*, *131*(5), 1029-36.

52. Jenkins NC, Liu T, Cassidy P, **Leachman SA**, Boucher KM, Goodson AG, Samadashwily G, Grossman D. (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. *Oncogene*, *30*(3), 265-74.

53. Moos PJ, Olszewski K, Honeggar M, Cassidy P, **Leachman S**, Woessner D, Cutler NS, Veranth JM. (2011). Responses of human cells to ZnO nanoparticles: a gene transcription study. *Metallomics*, *3*(11), 1199-211.

54. Pho LN, Smith FJ, Konecki D, Bale S, McLean WH, Cohen B, Eliason MJ, **Leachman SA**. (2011). Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. *Arch Dermatol*, *147*(9), 1077-80.

55. Sondak VK, **Leachman SA**. (2011). Individualizing follow-up for patients with early-stage melanoma. *J Clin Oncol*, *29*(35), 4606-8.

56. Wilson NJ, **Leachman SA**, Hansen CD, McMullan AC, Milstone LM, Schwartz ME, McLean WH, Hull PR, Smith FJ. (2011). A large mutational study in pachyonychia congenita. *J Invest Dermatol*, *131*(5), 1018-24.

57. Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, **Leachman SA**, Marghoob AA, Ming ME, Grichnik JM. (2012). Survival is not the only valuable end point in melanoma screening. *J Invest Dermatol*, *132*(5), 1332-7.

58. Eliason MJ, **Leachman SA**, Feng BJ, Schwartz ME, Hansen CD. (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. *J Am Acad Dermatol*, *67*(4), 680-6.

59. Gruber R, Edlinger M, Kaspar RL, Hansen CD, **Leachman S**, Milstone LM, Smith FJ, Sidoroff A, Fritsch PO, Schmuth M. (2012). An appraisal of oral retinoids in the treatment of pachyonychia congenita. *J Am Acad Dermatol*, *66*(6), e193-9.

60. Kasparian NA, Branstrom R, Chang YM, Affleck P, Aspinwall LG, Tibben A, Azizi E, Baron-

Epel O, Battistuzzi L, Bruno W, Chan M, Cuellar F, Debniak T, Pjanova D, Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky PA, **Leachman S**, Bergman W, Heisele O, Palmer J, Peric B, Puig S, Schadendorf D, Gruis NA, Newton-Bishop J, Brandberg Y. (2012). Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. *Arch Dermatol*, *148*(10), 1142-51.

61. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, **Leachman S**, Cannon-Albright L. (2012). A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. *Hum Genet*, *131*(1), 77-85.

62. Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, **Leachman SA**, Noyes RD. (2013). Sentinel lymph node Biopsy for melanoma in pregnant women. *Ann Surg Oncol*, *20*(2),689-96

63. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, **Leachman SA**. (2013). Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. *Psychooncology*, *22*(2), 276-89.

64. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, **Leachman SA**. (2013). Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. *Cancer Epidemiol Biomarkers Prev*, *22*(10), 1687-97.

65. Averbook B, Lee SJ, Delman K, Gow K, Zager J, Sondak V, Messina J, Sabel M, Pitteklow M, Ecker P, Markovic SN, Sweeter S, **Leachman SA**, Testori A, Curiel-Lewandrowski C, Go RS, Jukic D, Kirkwood J. (2013). Pediatric melanoma: analysis of an international registry. *Cancer, 119*(22), 4012-9.

66. Cannon-Albright LA, Teerlink CC, Farnham JM, Thomas AW, Zone JJ, **Leachman SA**. (2013). Linkage analysis of extended high-risk pedigrees replicates a cutaneous malignant melanoma predisposition locus on chromosome 9q21. *J Invest Dermatol*, *133*(1), 128-34.

67. Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, **Leachman SA**. (2013). Selenium for the prevention of cutaneous melanoma. *Nutrients*, *5*(3), 725-49.

68. Hawkes JE, Campbell J, Garvin D, Cannon-Albright L, Cassidy P, **Leachman SA**. (2013). Lack of GNAQ and GNA11 germ line mutations in familial melanoma pedigrees with uveal melanoma or blue nevi. *Front Oncol, 3*, 160.

69. Hawkes JE, Cassidy PB, Manga P, Boissy RE, Goldgar D, Cannon-Albright L, Florell SR, **Leachman SA**. (2013). Report of a novel OCA2 gene mutation and an investigation of OCA2 variants on melanoma risk in a familial melanoma pedigree. *J Dermatol Sci*, *69*(1), 30-7.

70. Pfeffer L, Kopelovich L, Fan M, Pfeffer S, **Leachman SA**. (2013). Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. *OncoTarget*, *4*(1), 128-41.

71. Taber JM, Aspinwall LG, Leaf SL, Kohlmann W, **Leachman SA**. (2013). Partner involvement in conduct of skin self-examination remains low following CDKN2A/p16 genetic test reporting and counseling. *J Am Acad Dermatol*, *69*(5), 842-4.

72. Aspinwall LG, Taber JM, Kolmann W, Leaf SL, **Leachman SA**. (2014). Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall. *J Genet Couns, 23*(3), 421-37.

73. Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, **Leachman SA**. (2014). Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. *Genet Med, 16*(11), 846-53.

74. Domyan ET, Guemset MW, Kronenberg Z, Kristnan S, Boissy RE, Vickrey AI, Rodgers C, Cassidy P, **Leachman SA**, Fondon JW, Randell M, Shapiro M. (2014). Epistatic and combinatorial effects of pigmentary gene mutations in the domestic pigeon. *Curr Biol*, *24*(4), 459-64.

75. Linden KG, **Leachman SA**, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr. (2014). A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. *Cancer Prev Res (Phila), 7*(5), 496-504.

76. Terakedis BE, Anker CJ, **Leachman SA**, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC. (2014). Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. *J Am Acad Dermatol, 70*(3), 435-42.

77. Aspinwall LG, Stump TK, Taber JM, Kohlmann W, Leaf SL, **Leachman SA**. (2015). Impact of melanoma genetic test reporting on perceived control over melanoma prevention. *J Behav Med, 38*(5), 754-65.

78. Taber JM, Aspinwall LG, Stump TK, Kohlmann W, Champine M, **Leachman SA**. (2015). Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. *J Behav Med, 38*(5):740-53.

79. Cassidy PB, Honeggar M, Poerschke RL, White K, Florell SR, Andtbacka RH, Tross J, Anderson M, **Leachman SA**, Moos PJ. (2015). The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. *Pigment Cell Melanoma Res, 28*(6), 685-95.

80. Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, **Leachman SA**, Pfeffer LM. (2015).Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. *J Clin Med, 4*(12), 2012-27.

81. Wu YP, Aspinwall LG, Michaelis TC, Stump T, Kohlmann WG, **Leachman SA**. (2016). Discussion of photoprotection, screening, and risk behaviors with children and grandchildren after melanoma genetic testing. *J Behav Med, 7*(1), 21-31.

82. Lund AW, Medler TR, **Leachman SA**, Coussens LM. (2016). Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. *Cancer Discov*, *6*(1), 22-35.

83. Taylor NJ, Handorf EA, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarrà G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, **Leachman SA**, Mann GJ, Nagore E, Olsson H, Palmer J, Perić B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KA, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL

Consortium. (2016). Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. *J Invest Dermatol, 136*(5), 1066-9.

84. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, **Leachman SA**, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. *Oncotarget, 7*(39), 64390-64399.

85. Wu YP, Aspinwall LG, Nagelhout E, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Cassidy P, **Leachman SA**. (2018). Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. *J Cancer Educ*, *33*(4), 774-781

86. Cassidy PB, Liu T, Florell SR, Honeggar M, **Leachman SA**, Boucher KM, Grossman D. (2017). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. *Cancer Prev Res (Phila), 10*(1), 36-44.

87. Eroh GD, Clayton FC, Florell SR, Cassidy PB, Chirife A, Marón CF, Valenzuela LO, Campbell MS, Seger J, Rowntree VJ, **Leachman SA**. (2017). Cellular and Ultrastructural Characterization of the Grey-Morph Phenotype in Southern Right Whales (Eubalaena australis). *PLoS One*, *12*(2):e0171449.

88. Webster DE, Suver C, Doerr M, Mounts E, Domenico L, Petrie T, **Leachman SA**, Trister AD, Bot BM. (2017). The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. *Scientific Data*, *4*:170005.

89. Rojek NW, Korcheva V, **Leachman SA**. A Large Skin-colored Nodule on the Plantar Foot: A Quiz. (2017). *Acta Derm Venereol, 97*(10), 1265-1266.

90. Mitra N, Goldstein AM, Tucker MA, Avril M, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes A, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Hoiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, **Leachman SA**, Mann GJ, Nagore E, Olsson H, Palmer JM, Peric B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton-Bishop JA, Gruis NA, Kanetsky PA. (2017). Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families. *J Invest Dermatol, 137*(12), 2606-2612.

91. Chen LL, Zhu J, Schumacher J, Wei C, Ramdas L, Prieto VG, Jimenez A, Velasco MA, Tripp SR, Andtbacka RHI, Gouw L, Rodgers GM, Zhang L, Chan BK, Cassidy PB11, Benjamin RS,

Leachman SA, Frazier ML. (2017). SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions. *PLoS One, 12*(9), e0184154.

92. Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, **Leachman SA.** (2017). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns, 101(3), 452-459.

93. Zager, JS, Gastman, BR, **Leachman, S**, Gonzalez, RC, Fleming, MD, Ferris, LK, Ho, J, Miller, AR, Cook, RW, Covington, KR, Meldi-Plasseraud, K, Middlebrook, B, Kaminester, LH, Greisinger, A, Estrada, SI, Pariser, DM, Cranmer, LD, Messina, JL, Wayne, JD, Delman, KA, Lawson, DH, Gerami, P. (2018). Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer, 18(1), 130.

94. Nelson KC, Grossman D, Kim CC, Chen SC, Curiel-Lewandrowski CN, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming ME. (2018). Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol, 79(2), 367-369.

95. Wu YP, Kohlmann W, Curtin K, Yu Z, Hanson HA, Hashibe M, Parsons BG, Wong J, Schiffman JD, Grossman D, Leachman SA. (2018). Melanoma risk assessment based on relatives' age at diagnosis. Cancer Causes & Control, 29(2), 193-199.

96. Stump TK, Aspinwall LG, Kohlmann W, Champine M, Hauglid J, Wu YP, Scott E, Cassidy P, Leachman SA. (2018). Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress. J Genet Couns, 27(4), 955-967.

97. Aspinwall LG, Stump TK, Taber JM, Drummond DM, Kohlmann W, Champine M, **Leachman SA**. (2018). Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. Transl Behav Med, 8(1):29-43.

98. Schuitevoerder D, Heath M, Cook RW, Covington KR, Fortino J, **Leachman SA**, Vetto JT. (2018). Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. J Drugs Dermatol, 17(2), 196-199.

99. Wu YP, Parsons BG, Mooney R, Aspinwall LG, Cloyes K, Hay JL, Kohlmann W, Grossman D, **Leachman SA**. (2018). Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. J Community Health, 43(5), 993-1001.

100. Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, **Leachman S**, Cannon-Albright LA. (2018). A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. *J Natl Cancer Inst*, *110*(12), 1380-1385.

101. Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes EK, Fahey JW, **Leachman SA**, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. (2018). Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi. *Cancer Prev Res (Phila), 11*(7), 429-438.

102. Zager J, Messina J, Gerami P, Wayne J, **Leachman SA**, Vetto J, Gastman B, Covington K, Cook R. (2019). Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. *Head & Neck, 41*(4), 871-879.

103. Abdel-Malek Z, Hernando Fuster B, Cassidy P, **Leachman S**, Kadekaro AL, Guard S, Anwar A, Swope V, Starner R. (2018). In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants. *Pigment Cell Melanoma Res, 32*(2), 259-268.

104. Stump TK, Aspinwall LG, Gray EL, Xu S, Maganti N, **Leachman SA**, Alshurafa N, Robinson JK. (2018). Daily Minutes of Unprotected Sun Exposure (MUSE) Inventory: Measure description and comparisons to UVR sensor and sun protection survey data. *Prev Med Rep*, *11*, 305-311.

105. Gastman BR, Gerami P, Kurley SJ, Cook RW, **Leachman S**, Vetto JT. (2019). Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. *J Am Acad Dermatol*, *80*(1), 149-157.e4.

106. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, **Leachman SA**. (2019). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. *Pediatric Dermatology, 36*(3), 317-323.

107. Parsons BG, Hay JL, Aspinwall LG, Zaugg K, Zhu A, Mooney RH, Klein SZ, Grossman D, **Leachman SA**, Wu YP. (2020). Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control. *J Cancer Educ*, *35*(3), 509-514

108. Chu A, André J, Rich P, **Leachman S**, Thompson CT. (2019). Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in-situ of the nail unit. *J Cutan Pathol, 46*(7), 479-483.

109. Wu YP, Parsons BG, Nagelhout E, Haaland B, Jensen J, Zaugg K, Caputo H, Lensink R, Harding G, Yancey J, Klein SZ, **Leachman SA**, Tercyak KP. (2019). A four-group experiment to improve Western high school students' sun protection behaviors. *Transl Behav Med*, *9*(3), 468-479.

110. Stump TK, Aspinwall LG, Drummond DM, Taber JM, Kohlmann W, Champine M, Cassidy PB, Petrie T, Liley B, **Leachman SA**. (2019). CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later. *Genet Med*, *22*(1), 26-34.

111. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, **Leachman SA**, Tercyak KP. (2019).A Pilot Study of a TeleHealth Family- Focused Melanoma Preventive Intervention for Children with a Family History of Melanoma. *Psychooncology*, *29*(1), 148-155.

112. Wu YP, Aspinwall LG, Parsons B, Stump TK, Nottingham K, Kohlmann W, Champine M, Cassidy P, **Leachman SA**. (2020). Parent and child perspectives on family interactions related to melanoma risk and prevention after CDKN2A/p16 testing of minor children. *J Community Genet*, *11*(3), 321-329. PMID: 31955387, PMCID: PMC7295919

113. Liu Y, **Leachman S**, Bar A. Proposed approach for reusing surgical masks in COVID-19 pandemic. (2020). *J Am Acad Dermatol, 83*(1):e53-e54. PMID: 32348829, PMCID: PMC7194514

114. Taber JM, Aspinwall LG, Drummond DM, Stump TK, Kohlmann W, Champine M, Cassidy P, **Leachman SA**. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma. (2021). *Ann Behav Med, 55*(1), 24-40. PMID: 32415830, PMCID: PMC7880221

115. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, **Leachman SA**, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. *JAMA Dermatol, 156*(9), 1004-1011. PMID: 32725204, PMCID: PMC8275355

116. Göğebakan KC, Berry EG, Geller AC, Sonmez K, **Leachman SA**, Etzioni R. (2020). Strategizing screening for melanoma in an era of novel treatments: a model-based approach. *Cancer Epidemiol Biomarkers Prev*, *29*(12), 2599-2607. PMID: 32958498

117. Kwatra SG, Hines H, Semenov YR, Trotter S, Holland E, **Leachman S.** (2020). A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma. *J Clin Aesthet Dermatol, 13*(11 Suppl 1):s3-s14. PMID: 33349788

118. Fried LJ, Tan A, Berry EG, Braun RP, Curiel-Lewandrowski C, Curtis J, Ferris LK, Hartman RI, Jaimes N, Kawaoka JC, Kim CC, Lallas A, **Leachman SA**, Levin A, Lucey P, Marchetti MA, Marghoob AA, Miller D, Nelson KC, Prodanovic E, Seiverling EV, Swetter SM, Savory SA, Usatine RP, Wei ML, Polsky D, Stein JA, Liebman TN. (2021). Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians: Results of a Modified Delphi Survey of Pigmented Lesion Experts. *JAMA Dermatol*, *157*(2), 189-197. PMID: 33404623

119. Yu WY, Hill ST, Chan ER, Pink JJ, Cooper K, **Leachman S**, Lund AW, Kulkarni R, Bordeaux JS. (2021). Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma. *J Invest Dermatol*, *141*(7), 1802-1809. PMID: 33417917, PMCID: PMC8238797

120. Petrie TC, Larson C, Heath M, Samatham R, Davis A, Berry EG, **Leachman SA**. (2021). Quantifying acceptable artefact ranges for dermatologic classification algorithms. *Skin Health and Disease*, https://doi.org/10.1002/ski2.19.

121. de Semir D, Bezrookove V, Nosrati M, Dar AA, Miller JR 3rd, Leong SP, Kim KB, Liao W, Soroceanu L, McAllister S, Debs RJ, Schadendorf D, **Leachman SA**, Cleaver JE, Kashani-Sabet M. (2021). Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma Susceptibility, *Cancer Res, 81*(11), 2956-296. PMID: 33766890, PMCID: PMC8178194

122. Gogebakan KC, Mukherjee K, Berry EG, Sonmez K, **Leachman SA**, Etzioni R. (2021). Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. *Cancer, 127*(16), 2926-2933. PMID: 33905529

123 Chang MS, **Leachman SA**, Berry EG, Curiel-Lewandrowski C, Geller AC, Grossman D, Kim CC, Stein JA, Swetter SM, Hartman RI. (2021). Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey. *Dermatol Online J, 27*(4), 13030/qt4sc3k9r0. PMID: 33999590

124. Orfaly VE, Berry EG, Stoos ER, Latour E, Becevic M, Black SM, Ferris LK, Geller A, Jacobe H, Nelson KC, Prasad S, Savory S, Smith EH, Swetter SM, Weinstock MA, Xu S, **Leachman SA**. (2021). Melanoma toolkit for early detection for primary care providers: A pilot study. *Pigment Cell Melanoma Res,* 2021 Feb 26. doi: 10.1111/pcmr.12968. Online ahead of print. PMID: 33638298

125. Ngamcherdtrakul W, Reda M, Nelson MA, Wang R, Zaidan HY, Bejan DS, Hoang NH, Lane RS, Luoh SW, **Leachman SA**, Mills GB, Gray JW, Lund AW, Yantasee W. (2021). In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. *Adv Mater*, 2021 Jun 12:e2100628. doi: 10.1002/adma.202100628. Online ahead of print. PMID: 34118167

Non-Peer Reviewed

1. Pho LN, **Leachman SA**. (2007). Genetic Testing for Familial Melanoma: Is It Right for You? *Skin Cancer Foundation Journal*, *25*: 23.

2. Pho LN, **Leachman SA**. (2010). Genetics of pigmentation and melanoma predisposition. *Giornale Italiano di Dermatologia e Venereologia*, *145*(1): 37-45.

Book Chapters

1. Stull JT, Bowman BF, Gallagher PJ, Herring BP, Hsu LC, Kamm KE, Kubota Y, **Leachman SA**, Sweeney HL, Tansey MG. (1989). Myosin phosphorylation in smooth and skeletal muscles: regulation and function. In Sperelakas N; Wood JD (Eds.), *Frontiers in Smooth Muscle Research*. New York: Wiley-Liss.

2. Smith FJD, Kaspar RL, Schwartz ME, McLean WHI, **Leachman SA**. (1993). Pachyonychia congenita. In: Pagon RA; Adam MP; Ardinger HH; Wallace SE; Amemiya A; Bean LJH; Bird TD; Fong CT; Mefford HC; Smith RJH; Stephens K (Eds.), *GeneReviews* [Internet]. Seattle,WA: University of Washington.
3. **Leachman SA**, Brandsma JL. (1998). Nucleic acid vaccines for immunization against papillomavirus induced lesions. In Tindle R (Ed.), *Human Papillomavirus Vaccines. Austin, TX:* Landes Bioscience.

4. Hanson N, **Leachman S**. (2001). Safety issues in isotretinoin therapy. In Thiboutot DM (Ed.), *Seminars in Cutaneous Medicine and Surgery* (*20.3*). London: Blackwell Science.
5. **Leachman SA**. (2001). Surgical therapies, part III: melanocyte transplants. In Bolognia J (Ed.), *Dermatologic Therap (14,* pp. 20-28). *Blackwell Science.*

6. **Leachman SA**, Lowstuter K, Wadge LM. (2004). Genetic testing for melanoma. In Rigel DS (Ed.), *Cancer of the Skin*. Philadelphia: Elsevier Saunders.

7. Choueiri TK, Olencki T, Samlowski WE, Florell SR, **Leachman SA**, Majer M, Vidimos A. (2006). Unusual cutaneous malignancies. In *Textbook of Uncommon Cancer* (3rd Edition). Wiley & Sons, Ltd.
8. **Leachman SA**, Reed BR. (2006). The use of dermatologic drugs in pregnancy and lactation. In *Dermatologic Clinics*. Philadelphia: Elsevier Saunders.

9. Aspinwall LG, Leaf SL, **Leachman SA**. (2009). Meaning and agency in the context of genetic testing for familial cancer. In Wong PTP (Ed.), *The Human Quest for Meaning* (2nd Edition). Hillsdale, NJ: Lawrence Erlbaum.

10. Cassidy PB, Grossman D, **Leachman SA**. (2012). Melanoma prevention. In Marincola FM; Ascierto P; Kirkwood JM (Eds.), Emerging Therapeutics for Melanoma. London: Future Medicine Ltd.

11. Aspinwall LG, Taber JM, Kohlmann W, **Leachman SA**. (2013). Psychological aspects of hereditary cancer risk counseling and genetic testing. In Carr BI; Steel J. (Eds.), *Psychological Aspects of Cancer* (pp. 31-64). Springer.

12. Cassidy PB, **Leachman SA**, Grossman D. (2013). N-acetylcysteine for reduction of oxidative stress/damage and melanoma. In Watson RR; Zibadi S (Eds.), *Bioactive Dietary Factors and Plant Extracts in Preventative Dermatology*. New York: Springer.

13. Grimaldi AM, Cassidy PB, **Leachman S**, Ascierto PA. (2014). Novel approaches in melanoma prevention and therapy. In Zappia V, et al. (Eds.), *Advances in Nutrition and Cancer, Cancer Treatment and Research 159*. Berlin: Springer-Verlag.

14. Quackenbush JF, Cassidy PB, Pfeffer LM, Boucher KM, Hawkes JE, Pfeffer L, Kopelovich SR, **Leachman SA** (2014). Isolation of Circulating MicroRNAs from Microvesicles Found in Human Plasma. In Thurin M; Marincola FM (Eds.), *Molecular Diagnostics for Melanoma: Methods and Protocols. Molecular diagnostics for melanoma.* New York: Springer.

15. Cassidy PB, **Leachman SA**, Moos PJ. (2015). Selenium in skin cancer. In Preedy VR (Ed.), *Selenium: Chemistry, Analysis, Function and Effects*. London: Royal Society for Chemistry.

16. **Leachman SA**, Cassidy PB, Chen SC, Curiel C, Geller A, Gareau D, Pellacani G, Grichnik JM, Malvehy J, North J, Jacques SL, Petrie T, Puig S, Swetter SM, Tofte S, Weinstock MA. (2016). Methods of Melanoma Detection. In Kaufman HL; Mehnert JM (Eds.), *Melanoma, Cancer Treatment and Research 167*. Switzerland: Springer.

17. Curiel-Lewandrowski C, Stemwedel C, Chen SC, Ferris L, Gerami P, Green AC, Johnson M, Loescher LJ, Malvehy J, Marghoob AA, Martires K, Pellacani G, Petrie T, Puig S, Swetter S, Tkaczyk E, Wisco O, L**eachman S**. (2018). Methods of Melanoma Detection. In Riker A (Ed.), *Melanoma: Comprehensive Management*, New York: Springer.

18. Hamman KJ, Kohlmann W, **Leachman S**. (2018). Genetic Counseling. In Fisher D; Bastian B (Eds.), *Melanoma*. New York: Springer. https://doi.org/10.1007/978-1-4614-7322-0_8-1

19. Urba WJ, Curti BD, **Leachman SA**. (2018). Cancer of the Skin. In Jameson JL, et al. (Eds.), *Harrison's Principles of Internal Medicine*, 20th ed (72). McGraw-Hill Education.

20. Swetter S, Geller AC, **Leachman SA**, Kirkwood JM, Katalinic A, Gershenwald JE. (2019). Melanoma Prevention and Screening. In Balch C, et al. (Eds.), *Cutaneous Melanoma*. Springer Cham.

21. Curiel-Lewandrowski C, Novoa RA, Berry E, Celebi ME, Codella N, Giuste F, Gutman D, Halpern A, **Leachman S**, Liu Y, Liu Y, Reiter O, Tschandl P. (2019). Artificial Intelligence Approach in Melanoma. In Fisher D; Bastian B (Eds.), *Melanoma*. New York: Springer. https://doi.org/10.1007/978-1-4614-7147-9_43

22. Berry EG, Lucero OM, **Leachman SA.** (2021). Can We End Melanoma As We Know It? The Role of Early Detection in Defeating Deadly Skin Cancer. In Lee D; Faries M (Eds.), *Practical Manual for Dermatologic and Surgical Melanoma Management.* Springer Cham. https://doi.org/10.1007/978-3-030-27400-9_1

23. Orrin EJR, Cassidy PB, Kulkarni RP, Berry EG, **Leachman SA**. Melanoma Prevention. In Alain RM; Sahni D (Eds.), *Melanoma in Clinical Practice*. New York: Springer. In press.

Reviews & Meeting Reports

1. Kamm KE, **Leachman SA**, Michnoff CH, Nunnally MH, Persechini A, Richardson AL, Stull JT. (1987). Myosin light chain kinases and kinetics of myosin phosphorylation in smooth muscle cells. [Review]. *Prog Clin Biol Res*, *245*, 183-93.

2. Myosin phosphorylation in smooth and skeletal muscles: regulation and function. Stull JT, Bowman BF, Gallagher PJ, Herring BP, Hsu LC, Kamm KE, Kubota Y, Leachman SA, Sweeney HL, Tansey MG. Prog Clin Biol Res. 1990;327:107-26. PMID: 2181457 Review. No abstract available.

3. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, **Leachman SA**. (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. [Review]. *J Clin Oncol*, *21*(11), 2179-86.

4. Hull C, Larson A, **Leachman S**. (2003). Pharmacogenetic candidate genes for melanoma. [Review]. *Pharmacogenomics*, *4*(6), 753-65.

5. Hansen CB, Wadge LM, Lowstuter K, Boucher K, **Leachman SA**. (2004). Clinical germline genetic testing for melanoma. [Review]. *Lancet Oncol*, *5*(5), 314-9.

6. **Leachman SA**, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, Lunny DP, Milstone LM, van Steensel MA, Munro CS, O'Toole EA, Celebi JT, Kansky A, Lane EB. (2005). Clinical and pathological features of pachyonychia congenita. [Review]. *J Investig Dermatol Symp Proc*, *10*(1), 3-17.

7. **Leachman SA**, McLean WHI, Schwartz JN, Schwartz ME. (2005). Preface: Pachyonychia Congenita Symposium proceedings. *J Investig Dermatol Symp Proc*, *10*(1), 1-2.

8. Milstone LM, Fleckman P, **Leachman SA**, Leigh IM, Paller AS, van Steensel MA, Swartling C. (2005). Treatment of pachyonychia congenita. [Review]. *J Investig Dermatol Symp Proc*, *10*(1), 18-20.

9. Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, Joval I, van Steensel MA, Bjorck E, Callif-Daley F, Pals G, Collins P, **Leachman SA**, Munro CS, McLean WH. (2005). The genetic basis of pachyonychia congenita. [Review]. *J Investig Dermatol Symp Proc*, *10*(1), 21-30.

10. Pho L, Grossman D, **Leachman SA**. (2006). Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. [Review]. *Curr Opin Oncol*, *18*(2), 173-9.

11. **Leachman SA**, Jackson R, Eliason MJ, Larson AA, Bolognia JL. (2007). Management of melanoma during pregnancy. [Review]. *Dermatol Nurs*, *19*(2), 145-52, 161.

12. **Leachman SA**, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WH, Kaspar RL. (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. [Review]. *J Dermatol Sci*, *51*(3), 151-7.

13. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, **Leachman S**, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. (2009). Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. *Pigment Cell Melanoma Res*, *22*(5), 532-43.

14. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, **Leachman S**, Messina J, O'Day S, Ribas A, Sondak V. (2010). Meeting report from the Third Global Workshop on Melanoma. *Pigment Cell Melanoma Res*, *23*(5), e1-7.

15. Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E, Coudiere P, DiGiovanna JJ, Elias P, Fischer J, Fleckman P, Gina M, Harper J, Hashimoto T, Hausser I, Hennies HC, Hohl D, Hovnanian A, Ishida-Yamamoto A, Jacyk WK, **Leachman S**, Leigh I, Mazereeuw-Hautier J, Milstone L, Morice-Picard F, Paller AS, Richard G, Schmuth M, Shimizu H, Sprecher E, Van Steensel M, Taieb A, Toro JR, Vabres P, Vahlquist A, Williams M, Traupe H. (2010). Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. [Review]. *J Am Acad Dermatol*, *63*(4), 607-41.

16. Kaspar RL, **Leachman SA**, McLean WH, Schwartz ME. (2011). Toward a treatment for pachyonychia congenita: report on the 7th Annual International Pachyonychia Congenita Consortium Meeting. *J Invest Dermatol*, *131*(5), 1011-4.

17. **Leachman SA**, Smalley KSM, Grossman D, Bowen GM, Messina JL, Berwick M, Glass LF, Swetter SM, Sondak V. (2012). Joint melanoma meetings in Tampa enhance communication and collaboration, 2011 International Melanoma Congress, Tampa, Florida. [Review]. *Expet Rev Dermatol*, *7*(2), 129-131.

18. Abdel-Malek ZA, Swope VB, Starner RJ, Koikov L, Cassidy P, **Leachman S.** (2014). Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention. [Review]. *Arch Biochem Biophys, 563*, 4-12.

19. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, **Leachman S**, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. (2014). Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. *J Transl Med, 12*, 277.

20. Denat L, Kadekaro AL, Marrot L, **Leachman SA**, Abdel-Malek ZA. (2014). Melanocytes as instigators and victims of oxidative stress. [Review]. *J Invest Dermatol,134*(6), 1512-8

21. Kim CC, Swetter SM, Curiel-Lewandrowski C, Grichnik JM, Grossman D, Halpern AC, Kirkwood JM, **Leachman SA**, Marghoob AA, Ming ME, Nelson KC, Veledar E, Venna SS, Chen SC. (2015). Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. [Review]. *JAMA Dermatol, 151*(2), 212-8.

22. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, **Leachman SA**, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. (2016). The state of melanoma: challenges and opportunities. [Review]. *Pigment Cell Melanoma Res*, *29*(4). 404-16

23. Ransohoff KJ, Jaju PD, Tang JY, Carbone M, **Leachman S**, Sarin KY. (2016). Familial skin cancer syndromes: Increased melanoma risk. [Review]. *J Am Acad Dermatol, 74*(3):423-34.

24. Wu YP, Aspinwall LG, Conn BM, Stump T, Grahmann B, **Leachman SA**. (2016). A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. [Review]. *Prev Med*, *88*, 153-67.

25. Johnson MM, **Leachman SA**, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. [Review]. *Melanoma Management*, *4*(1), 13-37.

26. **Leachman SA**, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P. (2017). Identification, genetic testing, and management of hereditary melanoma. [Review]. *Cancer*

Metatstasis, *36*(1):77-90.

27. **Leachman SA**, Mengden Koon S, Korcheva VB, White KP. (2017). Assessing Genetic Expression Profiles in Melanoma Diagnosis. [Review]. *Dermatol Clin, 35*(4), 537-544.

28. Tarhini AA, Lorigan P, **Leachman S.** (2017) Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. *Am Soc Clin Oncol Educ Book, 37*, 651-660.

29. Winkelmann RR, Farberg AS, Glazer AM, Cockerell CJ, Sober AJ, Siegel DM, **Leachman SA**, High WA, Markowitz O, Berman B, Pariser DM, Goldenberg G, Rosen T, Rigel DS. (2017). Integrating Skin Cancer-Related Technologies into Clinical Practice. [Review]. *Dermatol Clin, 35*(4), 565-576.

30. Sobanko JF, Shao K, Pearl RL, **Leachman S**. (2018). United States Preventive Services Task Force Overstates Cosmetic Harms of Skin Cancer Screening. [Review]. J *Clin Aesthet Dermatol*, *11*(4), 52-53.

31. Tolar J, Bauer JW, Kaplan DH, **Leachman SA**, McGrath JA, Paller AS, Griffith-Bauer KA, Stemwedel CE, Kulesz-Martin MF. (2018). Montagna Symposium 2017-Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment. *J Invest Dermatol*, *138*(6), 1243-1248.

32. Jeter J, Bowles T, Curiel-Lewandrowski C, Swetter S, Filipp FV, Abdel-Malek Z, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu E, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra K, Marghoob A, Chen S, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto S, Hay J, Grossman D, Ellis DL, Kashani-Sabet M, Mangold A, Markovic S, Nelson K, Powers JG, Robinson JK, Sahini D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle R, Thompson J, Weinstock MA**, Leachman SA**, Cassidy PB. (2018). Chemoprevention Agents for Melanoma: A Path Forward into Phase 3 Clinical Trials. [Review]. *Cancer*, *125*(1), 18-44.

33. Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB. Chen S, D'Orazio JA, Fujita M, Goh B, Herlyn M, Indra AK, Larue L, **Leachman SA,** Poole CL, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF (2018). Frontiers in Pigment Cell and Melanoma Research. *Pigment Cell Melanoma Res, 31*(6), 728-735.

34. Petrie T, Samatham R, Witkowski AM, Esteva E, **Leachman SA.** (2019). Melanoma Early Detection: Big Data, Bigger Picture. [Review]. *J Invest Dermatol, 139*(1), 25-30.

35. MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research. Petrie T, Samatham R, Goodyear SM, Webster DE, Leachman SA. Semin Cutan Med Surg. 2019 Mar 1;38(1):E49-E56. doi: 10.12788/j.sder.2019.001. PMID: 31051024 Review.

36. **Leachman SA**, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kramer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF. (2020). Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. *J Invest Dermatol*, *140*(2), 269-274.

37. Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, **Leachman SA**, Swetter, SM. (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. [Review]. *Melanoma Manag, 6*(4), MMT32.

Abstracts & Posters

1. Leachman SA, Brownstein DG, Chang E, Xiao W, Brandsma JL. (1997). Recruitment of MHC class II-positive lymphocytes into skin by intracutaneous innoculation of DNA encoding GM-CSF.

2. Leachman SA, Insogna KL, Katz L, Ellison A, Milstone LM. (1999). Effects of isotretinoin on gone density and calcium metabolism, Chicago, IL.

3. Leachman SA, DiMaio D, Zimmermann JW, Goodwin EC. (2001). Transcriptional alterations induced by papillomavirus E2 protein, Newport, RI.

4. Florell SR, Boucher KM, Leachman SA, Farrukh A, Harris RM, Malone J. (2002). Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Poster session presented at International Academy of pathology Meeting, Chicago, IL.

5. Florell SR, Grossman D, Meyer LJ, Leachman SA. (2002). Apoptosis index of nevi in Utah kindred members with and without CDKN2A mutations, Los Angeles, CA.

6. Florell SR, Porter-Gill PA, Schmidt S, Leachman SA. (2002). Fibrin cell plug method to confirm nevomelanocytic cell lineage, Amsterdam.

7. Leachman SA, Hansen C, Wadge L, Porter-Gill PA, Florell SR, Swinyer L. (2002). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.

8. Florell SR, Meyer LJ, Boucher KM, Porter-Gill P, Erickson H, Cannon-Albright LA, Harris R, Samlowski W, Zone JJ, Leachman SA. (2003). Phenotypic observations of a Utah melanoma kindred: fifteen years later.

9. Florell SR, Porter-Gill PA, Schmidt SA, Erickson H, Leachman SA. (2003). Rapid quantitation of immunostained cultured cells in a formalin-fixed, paraffin-embedded fibrin cell block.

10. Leachman SA, Porter-Gill PA, Erickson H, Schmidt S, Judd J, Florell SA. (2003). Cyclin-dependent kinase 2A function in the Familial Melanoma Syndrome.

11. Pond CD, Leachman SA, Warters RL. (2003). Accumulation and activation of the p53 protein in human skin in response to ionizing radiation. Poster session presented at American Association for Cancer Research, Washington, D.C.

12. Pond CD, Leachman SA, Warters RL. (2003). Post-translational modifications of DNA damage response proteins as a measure of cellular response to low doses of ionizing radiation. Poster session presented at Contractors Meeting, United States Dept of Energy, Washington, D.C.

13. Warters RL, Pond CD, Adamson PJ, Leachman SA. (2003). Ionizing radiation-induced DNA

damage response in cultured human skin cells.

14. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Leachman SA. (2004). Prevalence of CDKN2A mutations in familial melanoma. Poster session presented at American Society of Human Genetics, Toronto, Ontario, Canada.

15. Porter-Gill A, Erickson HM, Eller MS, Florell SR, Gilchrest BA, Leachman SA. (2004). p16 mutational status influences responses to T-oligo-simulated DNA damage. Poster session presented at The Society for Investigative Dermatology, Providence, RI.

16. Warters RL, Adamson P, Pond CD, Leachman SA. (2004). Micronucleus induction by ionizing radiation in primary skin cells. Poster session presented at Radiation Research Meeting, St. Louis, MO.

17. Liao H, Stewart A, Leachman SA, McLean W, Smith FJ. (2005). Molecular genetic analysis of 31 pachyonychia congenita families. Poster session presented at The Society for Investigative Dermatology, St. Louis, MO.

18. Ridky TW, Yang E, Leachman SA, Khavari P. (2005). The structural integrity of individual keratin filament networks is dispensable for epidermal tumorigenesis. Poster session presented at The Society for Investigative Dermatology, St. Louis, MO.

19. Warters RL, Williams DL, Pond CD, Leachman SA. (2005). Protein phosphorylation in irradiated human cells. Poster session presented at Radiation Research Society Annual Meeting, Denver, CO.

20. Eliason MJ, Milstone LM, Leachman SA. (2006). A comparison of patient experience with published treatments of pachyonychia congenital. Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.

21. Leachman SA, Eliason MJ, Benson N, Malmstrom S, McLean WH, Milstone LM, Kaspar R, Calebi JT, Smith FJ. (2006). Non-invasive analysis of keratin expression for pachyonychia congenita clinical trials. Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.

22. Smith FJD, Hickerson RP, Liao H, Sayers J, Leachman SA, Leake D, Kaspar RL, McLean WHI. (2006). Development of therapeutic siRNAs for treatment of pachyonychia congenita. Poster session presented at ESDR Meeting, Paris, France.

23. Warters RL, Zhuplatov SB, Williams DL, Pond CD, Leachman SA. (2006). Assessment of p53 protein expression in human skin models. Poster session presented at 45th Annual Meeting of the American Society for Cell Biology, San Diego, CA.

24. Warters RL, Zhuplatov SB, Williams DL, Pond CD, Leachman SA. (2006). Assessment of the p53 response of keratinocytes in culture and in intact human skin. Poster session presented at DOE Low Dose Radiation Research Program: Workshop VI, Washington, DC.

25. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee R, Grossman D. (2006).

Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Poster session presented at The Society for Investigative Dermatology, Philadelphia, PA.

26. Abdel-Malek ZA, Kadekaro AL, Kavanagh R, Swope V, Leachman SA. (2007). Molecular mechanisms for increased melanoma susceptibility by loss of function of MC1R. Poster session presented at Pan American Society for Pigment Cell Research (PASPCR), Chicago, IL.

27. Cai Q, Cassidy P, Manga P, Florell SR, Cannon-Albright L, Leachman SA. (2007). Molecular and phenotypic characterization of a new OCA2 mutation in humans. Poster session presented at Pan American Society for Pigment Cell Research (PASPCR), Chicago, IL.

28. Florell SR, Meyer LJ, Boucher KM, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA. (2007). Increased melanocytic nevi and nevus density in a G-34T CDKN2A melanoma-prone kindred. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.

29. Kaspar RL, Hickerson RP, Pho L, Leachman SA. (2007). Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and alters clinical symptoms in an off-label study in pachyonychia congenita patients. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.

30. Leachman SA, Boucher K, Cassidy P, Pimentel R, Mineau G, Cannon-Albright L, Florell S, Grossman D, Andtbacka R, Bowen G. (2007). A preliminary study of the design and feasibility of melanoma prevention trials. Poster session presented at International Melanoma Congress, New York, NY.

31. Pho L, Florell S, Harris R, Bowen A, Munro C, Liao H, Smith F, Leachman SA. (2007). Hair abnormalities are rare in pachyonychia congenital. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.

32. Pho L, Hicherson R, Kaspar R, Boucher K, McLean WH, Smith F, Leachman SA. (2007). Development and validation of an allele-specific quantitative RT-PCR assay for pachyonychia congenital. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.

33. Pho P, Liao H, Smith F, Konecki D, Bale S, McLean I, Cohen B, Eliason M, Leachman SA. (2007). Paternal germline mosaicism in pachyonychia congenital. Poster session presented at The Society for Investigative Dermatology, Long Beach, CA.

34. Warters RL, Zhuplatov SB, Hoenicke GF, Leachman SA, Moos PJ. (2007). Radiation-induced Stress Response in Human skin. Poster session presented at International Congress of Radiation Research (ICRR), San Francisco, CA.

35. Cassidy P, Fain H, Cassidy Jr. JP, Tran S, Moos P, Leachman SA. (2008). The effects of selenium on melanoma cells. Poster session presented at The American Association of Cancer Research (AACR), San Diego, CA.

36. Hickerson RP, Leachman SA, Pho LN, Smith FJ, Leake D, McLean W, Kaspar RL. (2008). Development of a PCR-based quantitative clinical endpoint to determine the effectiveness of siRNA therapy in a phase 1b trial in pachyonychia congenita patients. Poster session presented at International Investigative Dermatology, Kyoto, Japan.

37. Kaspar RL, Garcia M, Hicherson RP, Del Rio M, Leachman SA, Leake D, Milstone LM, Larcher F. (2008). Use of pachyonychia congenita patient-derived keratinocytes to 1) demonstrate the effectiveness of therapeutic TD101 siRNA and 2) generate a humanized mouse disease model. Poster session presented at International Investigative Dermatology, Kyoto, Japan.

38. Leachman SA, Hickerson RP, Schwartz ME, Smith FJ, McLean W, Milstone LM, Kaspar RL. (2008). First-in-skin siRNA clinical trial for pachyonychia congenita. Poster session presented at International Investigative Dermatology, Kyoto, Japan.

39. Warters RL, Zhuplatov S, Leachman SA. (2008). The nuclear matrix phosphoproteome of skin cells and their cancers. Poster session presented at The American Association of Cancer Research (AACR), San Diego, CA.

40. Wilson NJ, Messenger AG, Leachman SA. (2008). Keratin K6c mutations cause focal keratoderma. Poster session presented at International Investigative Dermatology, Kyoto, Japan.

41. Abdel-Malek ZA, Kadekaro AL, Swope V, Starner R, Supp D, Wakamatsu K, Ito S, Cassidy P, Leachman SA. (2009). Correlation of the MC1R genotype with the UV response of human melanocytes: implications on melanoma susceptibility. Poster session presented at 15th PanAmerican Society for Pigment Cell Research Conference, Memphis, TN.

42. Harris K, Florell SR, Papenfuss J, Kohlmann W, bowen GM, Leachman SA. (2009). Multiple pagetoid spitz nevi. Poster session presented at The Society of Investigative Dermatology, Montreal, Canada.

43. Hickerson RP, Leachman SA, Pho LN, Smith FD, McLean W, Leake D, Milstone LM, Kaspar RL. (2009). Further pre-clinical characterization of TD101 - the first siRNA to enter clinical trials for a skin disorder. Poster session presented at The Society of Investigative Dermatology, Montreal, Canada.

44. Leachman SA, Hicherson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FD, McLean W, Milstone LM, Kaspar RL. (2009). Mutation-specific siRNA resolves callus in a pachyonychia congenita patient. Poster session presented at The Society of Investigative Dermatology, Montreal, Canada.

45. Wilson LH, Gawlick U, Noyes RD, Florell S, Coleman L, Bowen A, Blaser J, Lundell R, Harris R, Bowen GM, Leachman SA, Grossman D, Andtbacka RHI. (2009). Sentinel lymph node biopsy in atypical spitzoid tumors. Poster session presented at The Society of Surgical Oncology, Phoenix, AZ.

46. Cassidy PB, Quackenbush J, Campbell J, Graham B, Agarwal C, Moos P, Grossman D, Leachman S. (2011). The natural product sulforaphane protects epidermal tissue of individuals at increased risk for melanoma from the effects of UV radiation. Poster session presented at AACR

Conference, Orlando, FL.

47. Hawkes JE, Campbell J, Garvin D, Cannon-Albright L, Cassidy P, Leachman SA. (2012). Familial melanoma pedigrees with an increased incidence of uveal melanoma and blue nevi: absence of germline mutations in exon 5 of GNAQ and GNA11. Poster session presented at SMR Meeting, Los Angeles, CA.

48. Linden KG, Leachman SA, Zager JS, Jakowatx J, Viner JL, Barr RJ, Carpenter PM, McLaren CM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran A, Meyskens F. (2012). A clinical trial of lovastatin for reversing atypia in nevi. Presented at Society for Melanoma Research 2012 Congress.

49. Wu YP, Aspinwall LG, Grahmann B, Mooney R, Kohlmann W, Leachman S. (2016). Why do children at elevated risk for melanoma not engage in preventive behaviors? Ann Behav Med, 50 (Suppl 1):S1-S335. Poster presented at The Society of Behavioral Medicine Annual Meeting, Washington, DC.

50. Lisa G. Aspinwall, Tammy K. Stump, Jennifer M. Taber, Wendy Kohlmann, Marjan Champine, Danielle Drummond, Pamela Cassidy, Sancy Ann Leachman. (2017). Melanoma genetic testing promotes reductions in tanning: Results from the Utah BRIGHT Project. ASCO Annual Meeting, Chicago, IL.

51. John T. Vetto, Sancy Leachman, Brooke M. Middlebrook, Kyle R. Covington, Jeffrey D. Wayne, Pedram Gerami, Jonathan S. Zager. (2017). Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head & neck. ASCO Annual Meeting, Chicago, IL.

52. Nagelhout ES, Grahmann-Parsons B, Patil A, Aspinwall L, Boucher KM, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA, Wu YP. (2017). Delivery of Novel Educational Intervention to Increase Knowledge and Perceived Risk for Melanoma among Children with Familial Risk for Melanoma. Annual American Public Health Association Conference, Atlanta, GA.

53. Leachman, SA, Stoos, E, Cassidy, P, Lapidus, J, Petrie, T, Sonmez, K, Berry, E, Etzione, R. (2019) War on Melanoma: Early Detection Campaign, Society for Investigative Dermatology Meeting, Washington, DC.

Case Reports

1. Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, **Leachman SA**. (2003). Pancreatic carcinoma surveillance in patients with familial melanoma. *Arch Dermatol*, *139*(8), 1019-25.

2. Alexander A, Harris RM, Grossman D, Bruggers CS, **Leachman SA**. (2004). Vulvar melanoma: diffuse melanosis and metastasis to the placenta. *J Am Acad Dermatol*, *50*(2), 293-8.

3. Oh Adib C, Jones B, Liao H, Smith FJ, Solomon R, Egan CA, **Leachman S**. (2008). Recurrent mutation in keratin 17 in a large family with pachyonychia congenita type 2. *Arch Dermatol Res*, *300*(5), 211-4.

4. Harris K, Hull PR, Hansen CD, Smith FJ, McLean WH, Arbiser JL, **Leachman SA**. (2012). Transgrediens pachyonychia congenita (PC): case series of a nonclassical PC presentation. *Br J Dermatol*, *166*(1), 124-8.

5. Harris K, Florell SR, Papenfuss J, Kohlmann W, Jahromi M, Schiffman JD, Quackenbush J, Cassidy P, **Leachman S**. (2012). Melanoma mimic: a case of multiple pagetoid Spitz nevi. *Arch Dermatol*, *148*(3), 370-4.

6. Ludzik J, Witkowski A, Hansel DE, Raess PW, White K, **Leachman S.** (2020). Case Report: Chilblains-like lesions (COVID-19 toes) during the pandemic - is there a diagnostic window? *F1000Res*, *9*, 668. PMID: 32913640, PMCID: PMC7459833.

7. Slaught C, Berry EG, Bacik L, Skalet AH, Anadiotis G, Tuohy T, **Leachman SA.** (2021). Clinical challenges in interpreting multiple pathogenic mutations in single patients. *Hered Cancer Clin Pract*, *19*(1), 15. PMID: 33541411.

Letters & Editorials

1. Florell SR, Boucher KM, Holden JA, Meyer LJ, Samlowski WE, Cannon-Albright LA, Zone JJ, Leachman SA. (2002). Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. [Letter to the editor]. J Invest Dermatol, 118(2), 386-7.

2. Milstone LM, Insogna KL, Leachman SA. (2005). Isotretinoin does have an adverse effect on bone mineral density. [Letter to the editor]. J Am Acad Dermatol, 53(1), 181; author reply 182-3.

3. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, Leachman SA. (2005). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. [Letter to the editor]. J Invest Dermatol, 125(6), 1310-2.

4. Cotter MA, Florell SR, Leachman SA, Grossman D. (2007). Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. [Letter to the editor]. J Invest Dermatol, 127(10), 2469-71.

5. Leachman S. (2007). Training with Aaron Lerner. [In Memoriam]. J Invest Dermatol, 127(9), 2094-6.

6. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA. (2008). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. [Letter to the editor]. J Invest Dermatol, 128(8), 2122-5.

7. Manga P, Hoek KS, Davids LM, Leachman SA. (2010). From melanocyte to malignant metastatic melanoma. [Editorial]. Dermatol Res Pract, pii: 798324.

8. Curtis JA, Tanner P, Hull CM, Leachman SA. (2015). Reply to “Nail curing UV lamps: Trivial exposure not cause for public alarm.” J Am Acad Dermatol, 73(5):e187.

9. Cassidy PB, Abdel-Malek ZA, Leachman SA. (2015). Beyond Red Hair and Sunburns: Uncovering the Molecular Mechanisms of MC1R Signaling and Repair of UV-Induced DNA Damage. [Commentary]. J Invest Dermatol, 135(12), 2918-21.

10. Leachman SA, Merlino G. (2017). Medicine: The final frontier in cancer diagnosis. [Commentary]. Nature, 542(7639), 36-38.

11. Varedi A, Wu YP, Klein SZ, Leachman SA, Grossman D. (2018). Mineral sunscreens not recommended by Consumer Reports: suggestions to improve the review process. [Commentary]. J Am Acad Dermatol, 80(3), 832-33.

12. Reply to Reimann et al. Clarke LE, Leachman SA. Mod Pathol. 2019 May;32(5):725-727. doi: 10.1038/s41379-018-0197-1. Epub 2019 Jan 21. PMID: 30666051 No abstract available.

13. Varedi A, Gardner LJ, Kim CC, Chu EY, Ming ME, Leachman SA, Curiel-Lewandrowski C, Swetter SM, Grossman D. (2020). Use of new molecular tests for melanoma by pigmented-lesion experts. [Research Letter]. J Am Acad Dermatol, 82(1), 245-247.
14. Reply to: Comments on “Proposed approach for reusing surgical masks in COVID-19 pandemic. Liu Y, Leachman SA, Bar A. J Am Acad Dermatol. 2020 Sep;83(3):e229. doi: 10.1016/j.jaad.2020.05.084. Epub 2020 May 22. PMID: 324468.

15. Faries MB, Ascierto PA, Blank C, Cochran AJ, Delman K, Gyorki D, Haanen J, Hamid O, Han D, Karakousis G, Kashani-Sabet M, Leachman S, Moncrieff M, Plasmeijer E, Enrico Testori AA, Van Akkooi A, Wong S, Zager JS. (2021). Letter Regarding Editorial by Samuel Zagarella. [Letter to the editor]. Am J Dermatopathol, 43(7), 539-541. PMID: 33264129

16. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. (2021).

17. The State of Melanoma: Emergent Challenges and Opportunities. [Perspective]. Clin Cancer Res, 27(10), 2678-2679.PMID: 33414132

Patents

1. Pershing LK, **Leachman SA**. (2005). Skin type assessment and nevi screening for skin cancer with a non-invasive portable reflectance spectrophotometer. U.S. Patent No. 11-115-646. Washington, D.C.:U.S. Patent and Trademark Office.

INVITED LECTURES, CONFERENCE PRESENTATIONS & PROFESSORSHIPS:

International

2004 "Prognostic Factors and Survival in Familial Melanoma," Second International Melanoma Research Congress, Phoenix, AZ

2004 "An Ounce of Prevention, Sunscreens, and More," Winter Skin Seminar, Whistler, British Columbia, Canada

2004 "Hereditary Melanoma: Management of High Risk Patients," Winter Skin Seminar, Whistler, British Columbia, Canada

2005 "Pros & Cons of Genetic Testing," Sixth World Congress on Melanoma, Vancouver, British Columbia, Canada

2005 "Familial Melanoma: A Model for Translational Melanoma Research," University of Maastricht, The Netherlands

2005 "Update on Utah Melanoma Families," The Melanoma Consortium Meeting, Leiden, The Netherlands

2005 "Contemporary Management of the Dysplastic Nevus Syndrome," Second International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY

2006 "What You Need to Know About Pachyonychia Congenita," Pachyonychia Congenita Patient Support Meeting, Scotland

2006 "Hereditary Melanoma," Third International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY

2006 "Population-based Assessment of CDKN2A and Melanoma-associated Non-melanoma Cancer Incidence in Utah," Annual GenoMEL Meeting, Genoa, Italy

2007 "Progress on Pachyonychia Congenita," 1st World Congress on Genodermatology, Maastricht, The Netherlands

2007 "Genetic Differences Among Patients Based on Sun Exposure," Fourth International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY

2007 "Etiology, Epidemiology, and Molecular Biology: Implications for Therapeutic Intervention," First Global Workshop on Malignant Melanoma (PER), Puerto Rico

2008 "The Missing (Older) Man: How Can We Reach the People Most in Need of Skin Screening?" 2nd Annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers Meeting, Clearwater Beach, FL

2008 "Should Genetic Testing be Used Clinically?" 5th International Symposium on Melanoma and Other Cutaneous Malignancies, New York, NY

2008 "How Genetic Test Reporting Affects Patient Screening and Adherence to Surveillance Recommendations," GenoMEL Conference, Paris, France

2009 "Genetherapy of Keratin Disorders," Ichthyosis Consensus Conference, Soreze, France

2009 "First-in-Skin siRNA Clinical Trial," Keystone Symposia: Therapeutic Modulation of RNA Using Oligonucleotides, Alberta, Canada

2009 "The Genetic Counseling Package," GenoMEL Melanoma Genetics Consortium Meeiting, Ljubljana, Slovenia

2009 "TD101 Clinical Trial: Intradermal Injection of siRNA," International PC Consortium, Montreal, Quebec, Canada

2009 "Melanoma Genetic Counseling and Testing Improves Patient Compliance and Perceived Control," 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers Conference, Berlin, Germany

2010 "Genetics of Melanoma: Impact on Diagnosis and Therapeutic Decisions," International Hematology/Oncology Forum: Spotlight on Melanoma, CML and Breast Cancer, Cancun, Mexico

2010 "Protection of UV-irradiated Epidermal Tissue from Donors with Loss-of-Function MC1R Genotypes by the Natural Product Sulforaphane," Pan American Society for Pigment Cell Research, Vancouver, BC, Canada

2011 "Genetic Counseling and Testing for Hereditary Melanoma Educational Package," GenoMEL Annual Conference, Israel

2011 "Hereditary Melanoma," 22nd World Congress of Dermatology, Seoul, Korea

2011 "The Role of Melanoma Genetic Testing in Prevention and Early Detection," Melanoma Research: A Bridge from Naples to the World, Naples, Italy

2011 "Novel Treatments for Keratin Mutations in Pachyonychia Congenita," Montagna Symposium on the Biology of Skin, Skamania, WA, October 2011

2013 "Cancer Prevention: What Will It take?" Milken Institute Global Conference, Los Angeles, CA

2013 "Melanoma Susceptibility Genes," 8th World Congress of Melanoma, Hamburg, Germany, July 2013

2013 "Melanoma Risk and Prevention: A Story of Pigmentation, Genetics, and Environment," Montagna Symposium of the Skin, Skamania, WA, October 2013

2013 "Melanoma Prevention Update," XIX Annual Meeting of the Italian Melanoma Intergroup (IMI), Naples, Italy, December 2013

2013 "The Role of Melanoma Genetic Testing in Prevention and Early Detection," Melanoma Bridge 2013, Naples, Italy, December 2013

2015 "An International Melanoma Community Registry: Where Do We Go from Here?" International Melanoma Working Group, Marseille, France, October 2015

2015 "Mole Mapper- A Paradigm Shift in Clinical Research for Early Detection of Melanoma," Society for Melanoma Research, San Francisco, CA, November 2015

2016 "Anti-oxidants and Pro-metastatic Behavior of Melanoma in Mice & Humans," International Melanoma Working Group, Zagreb, Croatia, March 2016

2017 "How can the War on Melanoma's Impact Be Extended to MPWG?" and "Waging War on Melanoma: Early Detection in Oregon and Beyond," International Pigment Cell Conference (IPCC), Denver, Colorado, August 2017

2017 "Mole Mapper™ and the War on Melanoma," Montagna on the Biology of Skin, Skamania, WA, October 2017

2018 "It's All About the Melanocyte," Melanoma, Vitiligo and XP Patient Symposium (Montagna Symposium/PASPCR Annual Meeting pre-conference), Gleneden Beach, OR, October 17, 2018

2018 "War on Melanoma: Oregon and Beyond," MPWG Meeting at the Montagna Symposium/PASPCR Annual Meeting, Gleneden Beach, OR, October 20, 2018

2018 "Prevention and Early Detection of Melanoma," Society for Melanoma Research Annual Meeting, Manchester, UK, October 26, 2018

2019 "A Population-Based Screening Program versus Opportunistic Screening and Early Detection," Australian Skin & Skin Cancer Summit, Brisbane, AUS, March 25, 2019

2021 "Revolutionizing Diagnosis & Management of Skin Diseases," World Congress of Confocal Microscopy, Virtual lecture, May 22, 2021

National

1996 "On the Border of Vitiliginous Versus Pigmented Skin," Pigment Club, American Academy of Dermatology, Washington, DC

1999 "Unusual Dermal Melanocytosis," Pigment Club, American Academy of Dermatology, New Orleans, LA

2000 "Isotretinoin and Bone Density," American Academy of Dermatology's Academy, Nashville, TN

2001 "Hereditary Melanoma," Yale University School of Medicine, Department of Dermatology Grand Rounds and Noon Lecture Series, New Haven, CT

2001 Melanoma Research Foundation Symposium

2001 "Melanocyte Transplantation for the Treatment of Vitiligo," Annual Meeting, American Academy of Dermatology, Anaheim, CA

2001 "Papillomavirus: From Verruca Vulgaris to Squamous Cell Carcinoma, Clinical Disease & Its Molecular Basis," American Academy of Dermatology 59th Annual Meeting, Washington, DC

2001 "Hereditary Melanoma," Department of Dermatology Grand Rounds and Noon Lecture Series, New Haven, CT

2003 "Is It Time for Genetic Testing for Melanoma?" Invited lecturer at the American Academy of Dermatology 2003 Meeting, San Francisco, CA

2003 "Diagnostic Targets for Early Detection of Melanoma," Invited speaker to CHI Conference, Santa Clara, CA

2003 "The Familial Melanoma Research Program in Utah," Invited speaker to Melanoma Consortium, Philadelphia, PA

2004 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, Washington, DC

2005 "The Role of Genetic Testing in Melanoma," Twenty-fourth Anniversary Fall Clinical Dermatology Conference, Las Vegas, NV

2005 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, New Orleans, LA

2005 "Drugs, Pregnancy, and the Skin" and "Melanoma Pregnancy," American Academy of Dermatology, New Orleans, LA

2006 "Hereditary Melanoma," 13th Annual PASPCR Meeting / The Melanocyte and its Environment, Cincinnati, OH

2006 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, San Francisco, CA

2007 "Genetic Testing for Melanoma Risk Stratification," Melanoma Care Coalition Regional Symposium, Cincinnati, OH

2007 "Screening for CDKN2A Mutations in Familial Melanoma: National Consensus" Melanoma Prevention Working Group (SWOG), Huntington Beach, CA

2007 "To Test or Not to Test: p16 Genetic Testing in Familial Melanoma," American Academy of Dermatology, Washington, DC

2008 "Cutaneous Cancer Syndromes," American Academy of Dermatology, San Antonio, TX

2008 "Structure and Function of the Skin - Nails and Pachyonychia Congenita," American Academy of Dermatology, San Antonio, TX

2008 "Bench to Bedside: Pachyonychia Congenita Project," 34th Annual Meeting Society of Pediatric Dermatology, Snowbird, UT

2008 "Population-based analysis of prognostic factors and survival in familial melanoma, data collection, management, what does it take?" SPORE Conference, New Haven, CT

2008 University of Massachusetts, Worchester, MA

2009 "Utilizing Utah Population Resources to Investigate Melanoma," University of New Mexico, Albuquerque, NM

2009 "siRNA Therapeutics for Pachyonychia Congenita," University of California/Irvine, Irvine, CA

2009 "Do I Need To Be Genetically Tested for Melanoma?" American Academy of Dermatology, San Francisco, CA

2009 "siRNA Therapeutics for the Treatment of Pachyonychia Congenita," American Academy of Dermatology, San Francisco, CA

2009 "An Ounce of Melanoma Prevention," 9th Annual Oncology Update: Advances and Controversies, Park City, UT

2009 "Population at Risk to Target for Melanoma Genetic Testing," American Academy of Dermatology, San Francisco, CA

2009 "Nails and Pachyonychia," American Academy of Dermatology, San Francisco, CA

2009 "Selenium for the Prevention and Treatment of Melanoma, 15th Meeting of PanAmerican Society for Pigment Cell Research, Memphis, TN

2009 "Mutation Specific siRNA Resolves Callus in a Pachyonychia Congenita Patient," 69th Annual Society for Investigative Dermatology Meeting, Montreal, Quebec, Canada

2009 "Current Understanding of the Genetics of Melanoma," Perspectives in Melanoma XIII, Baltimore, MA

2010 "The Role of Gene Mutations in New Therapies," AIM at Melanoma, Pittsburgh, PA

2010 "The Future – Clinical Trials and Studies," Society for Investigative Dermatology, Atlanta, GA

2010 "Frontiers in Preparing for Clinical Trials," Foundation for Ichthyosis and Related Skin Types, Orlando, FL

2010 "Nails and Pachyonychia Congenita," American Academy of Dermatology, Miami Beach, FL

2010 "Biological Therapies in Pregnancy," American Academy of Dermatology, Miami Beach, FL

2010 "Prevention Among High Risk Families," American Academy of Dermatology, Miami Beach, FL

2010 "Update on Melanoma Genetics," Atlanta Dermatological Association Conference, Atlanta GA

2010 “First-in-skin siRNA Therapeutic for Pachyonychia Congenita,” Atlanta Dermatological Association Conference, Atlanta, GA

2010 “Overview of Cutaneous Cancer Syndromes,” American Society of Clinical Oncology, Chicago, IL

2010 “Hereditary Melanoma: New Developments,” 10th Annual Cancer Conference, Canton, OH

2012 “Gene-Environment Interactions in Melanoma,” American Society of Clinical Oncology, Chicago, IL

2012 “Melanoma Chemoprevention: Is it Time?” University of Utah Department of Dermatology Grand Rounds

2013 Presenter: “Clinical Assessment of UV Oncogenesis in Human Melanoma and Its Precursors,” Moderator: “Epidemiology, Genetics, Prevention and Melanoma Biology” session, Perspectives in Melanoma, Baltimore, MD, September 2013

2013 “Melanoma Prevention Update,” Memorial Sloan Kettering Dermatopathology Grand Rounds Conference, New York, NY, October 2013

2013 “Melanoma Prevention Update,” Howard Koh Lecture (Grand Rounds), Boston University, August 2013

2015 “Reducing the Burden of Melanoma: Genetics, Prevention Behaviors, and Patient Advocacy,” Dermatology Grand Rounds Visiting Professor Lecture, New Haven, CT, July 2015

2015 “Melanoma Prevention Update,” Procter & Gamble Scientific Lectureship Series, Cincinnati, OH, April 2015

2015 “Melanoma Chemoprevention Pipeline: Are Antioxidants the Answer?” Yale Visiting Professor Lecture Series, New Haven, CT, July 2015

2015 “Tincture of Tigelaar: Translating Ideas into Hypotheses That Get Tested,” Robert Tigelaar Symposium, New Haven, CT, September 2015

2015 “Clinical Pearls,” Winter Clinical Dermatology Conference, Maui, HI

2015 “Melanoma Update & Controversies in Skin Cancer Management, Prevention & Treatment,” American Academy of Dermatology, San Francisco, CA

2015 “Melanoma Genetics: Risk & Diagnostic Implications,” Real World Dermatology for Residents, Las Vegas, NV, June 2015

2016 “Mole Mapper: An iPhone App to Measure Moles,” Melanoma Research Alliance, Washington, DC, February 2016

2016 “Genetics, Molecular Profiling and Epidemiology of Early Stage Melanoma,” Winship Cancer Institute: 2016 Melanoma Conference, Atlanta, GA, February 2016

2016 "Vitiligo and Pigmentary Disorders" OHSU Department of Dermatology Grand Rounds, Portland OR, January 2016

2016 "Mole Mapper," AMIA 2016 – Joint Summits on Translational Science, San Francisco, CA, March 2016

2017 "Prevention and Screening of Melanoma," Leland R. Cowan Cancer Symposium Update on Diagnosis and Treatment of Melanoma, Salt Lake City, UT, February 2017

2017 "Waging War on Melanoma: Early Detection in Oregon & Beyond," Annual M. H. Samitz Lecture, University of Pennsylvania, Philadelphia, PA, November 2017

2018 "War on Melanoma: Taking It To The Streets with MoleMapper & Screening," Emory University, Winship Cancer Institute, Atlanta, GA, March 3, 2018

2018 "Oregon's War on Melanoma: Harnessing the Power of Early Detection," Kay Family Lectureship, Johns Hopkins University, Baltimore, MD, April 4, 2018

2018 "Technology & Early Detection of Melanoma," American Dermatology Association, Napa, CA, October 8, 2018

2018 "War on Melanoma: Early Detection in Oregon & Beyond," Everett C Fox Lectureship, Everett C. Fox Lectureship, University of Texas Southwestern, Dallas, TX, October 23, 2018

2018 "War on Melanoma: An Oregon Solution for Cancer Control," National Cancer Institute's Cancer Prevention Fellowship Program, Washington, DC, November 16, 2018

2019 "War on Melanoma: Oregon's Early Detection Experiment," American Association for Cancer Research: Melanoma from Biology to Target, Houston, TX, January 17, 2019

2019 "Genetic Testing for Melanoma: Who, What, When, Where & Why," University of Louiseville's Winter Skin Seminar, Park City, UT, January 28, 2019

2019 "War on Melanoma: Early Detection in Oregon & Beyond," OHSU Department of OBGYN, Portland, OR, January 2019

2019 "Early Detection of Melanoma: From Genetic Testing to Technology-Driven Educational Campaigns," HemOnc Today, New York City, NY, June 6, 2019

2019 "Early Detection of Melanoma: From Genetic Testing to Technology-Driven Educational Campaigns," John Wayne Cancer Institute, Los Angeles, CA, June 12, 2019

2019 "War on Melanoma," The Inova Schar Cancer Institute's Melanoma & Cutaneous Oncology Primer, Washington, DC, October 19, 2019

2019 "Melanoma detection: Different tools for different populations," Cutaneous Oncology Primer, Las Vegas, NV, November 5, 2019

2019 "Melanoma detection: Oregon's Public Health Experiment," Society for Melanoma Research, Salt Lake City, UT, November 21, 2019

2020 "War on Melanoma: Oregon's Early Detection Experiment," Werthan Lecture, Vanderbilt University, August 20, 2020

2020 "War on Melanoma: Oregon's Early Detection Experiment," Katie Rodan & Kathy Fields Lecture, Stanford University, November 12, 2020

2020 "Oregon's War on Melanoma: A Public Health Early Detection Experiment," Melanoma Research Alliance, Washington, DC, February 26, 2020

2020 "War on Melanoma: Oregon and Beyond," Melanoma Know More, Cincinnati, OH, February 29, 2020

2020 "Melanoma Epidimiology & Prevention," Melanoma Research Foundation, Los Angeles, CA, June 4, 2020 (Virtual lecture)

2020 "Melanoma detection: Different tools for different populations," Providence Internal Medicine, Portland, OR, January 22, 2020

2020 "Melanoma detection: Different tools for different populations," Kaiser Hospital, Portland, OR, February 5, 2020

2021 "What You Need to Know: Diagnosing Melanoma," Melanoma Research Alliance, Virtual lecture, April 15, 2021

2021 "Sharing Genetic Test Results with People at High Risk of Melanoma to Motivate Behavior Change, Virtual lecture, May 13, 2021

2021 "The Mystique of Feminine Leadership: Style & Practice," Women in Melanoma Conference, Virtual lecture, May 22, 2021

2021 "Practical Updates Recognizing Skin Cancer in Primary Care," Dermatology Week, Virtual lecture, July 17, 2021

REGIONAL

1999 "Autologous Melanocyte Transfer for Vitiligo," Westwood Squibb Winter Skin Seminar, Snowbird, UT

2001 "The Familial Melanoma Research Clinic," Director Series, Huntsman Cancer Institute, Salt Lake City, UT

2001 "The Familial Melanoma Research Clinic," Melanoma Research Foundation Symposium at HCI, Salt Lake City, UT

2002 "The Huntsman Cancer Institute Familial Melanoma Research Program," Guest Lecturer at the Arizona Cancer Center, Tucson, AZ

2002 "Is It Time for Clinical Genetic Testing for Melanoma?" Invited speaker for Myriad Genetics, Salt Lake City, UT

2002 "Clinical Genetic Testing for Melanoma," Invited speaker at the Utah Dermatologic and Surgical Society Meeting, Zion, UT

2004 "Let the Sunshine In, But Protect Your Skin!" Speaking of Women's Health, local meeting of national conference, Salt Lake City, UT

2004 "The Melanoma Program at Huntsman Cancer Institute," Arizona Cancer Center, University of Arizona, Tucson, AZ

2005 "Skin Flix: Genetic Traits and Skin Cancer," University of Utah for the Genetic Science Learning Center, Natural History Museum, Salt Lake City, UT

2005 "Genetic Testing for Hereditary Melanoma," Utah Cancer Registry, LDS Hospital, Salt Lake City, UT

2006 "Pros & Cons of Melanoma Genetic Testing," Myriad Genetics, Inc., University Park Marriott Hotel, Salt Lake City, UT

2006 "Sun Safety: Protecting Our Children's Skin," Davis School District Fall Workshop, Bountiful, UT

2006 "Hereditary Melanoma: Where Do We Stand?" St. Joseph Hospital Regional Cancer Center Ninth Annual Melanoma Symposium, The Balboa Bay Club & Resort, Newport Beach, CA

2008 "Genetic Testing for Melanoma Risk Stratification," Pacific Dermatology Association Annual Meeting, San Francisco, CA

2008 "Discover the 'Super Powers' of Smart Skincare," Speaking of Women's Health, Salt Lake City, UT

2010 "Melanoma in Pregnancy," Current Trends in the Genetics of Melanoma and Clinical Implications, Tucson, AZ

2010 "Update on Hereditary Melanoma," Current Trends in the Genetics of Melanoma and Clinical Implications, Tucson, AZ

2013 "Melanoma Genetics and Prevention Update" and "NCI-Designated Cancer Institute," Oregon Dermatology Society Annual Meeting, Sunriver, OR, August 2013

2013 "Melanoma Prevention Update," Oregon State Cancer Registry Fall Workshop, Kaiser, OR, September 2013

2013 "Melanoma Prevention Update," Pommerening Invited Lectureship, University of Washington Dermatology Department, October 2013

2013 "Melanoma Prevention Update," NW Oregon Dermatology Nurses Association, Bend, OR, November 2013

2014 "Melanoma Prevention Update," OHSU 45th Annual Primary Care Review, Portland, Oregon, February 11, 2014

2015 "What's New in Vitiligo?" Pacific Dermatology Association Annual Meeting, Park City, UT

2015 "The War on Melanoma," Pacific Dermatology Association Annual Meeting, Park City, UT, Epstein Lecture

2015 "Declaring War on Melanoma," OHSU Marquam Hill Lecture Series, Portland, OR May 2015

2016 What You Need to Know if You Haven't Had Skin Cancer…Yet," War on Skin Cancer Event, Portland, OR, May 21, 2016

2017 "Melanoma and the Deep Learning Revolution," Center for Spoken Language Understanding, Portland, OR, March 21, 2017

2017 "Melanoma Prevention and Self Skin Exams," Melanoma Community Research Forum, Portland, OR, January 21, 2017

2017 "War on Melanoma Progress and Updates," Virtual Melanoma Educational CME Update, Portland, OR, January 21, 2017

2017 "Gene Expression Profile Tests," War on Melanoma Scientific CME Symposium, Portland, OR, May 20, 2017

2017 "Waging War on Melanoma: Early Detection in Oregon & Beyond," M. H. Samitz Lecture, Philadelphia, PA, November 9, 2017

2017 "Waging War on Melanoma – Early Detection in Oregon & Beyond," Melanoma Patient and CME Symposium, Portland, OR, November 18, 2017

2018 "War on Melanoma: Taking It to the Streets With MoleMapper & Screening," Winship Cancer Institute 2018, Atlanta, GA, March 3, 2018

2018 "Oregon's War on Melanoma: Patient Driven Research Efforts and Prevention & Detection," Oregon State University, Student Health Services CME, Corvallis, OR, April 17, 2018

2018 "Oregon's War on Melanoma: An Update," PDX Skin Care Festival, Portland, OR, May 19, 2018

2018 "Oregon's War On Melanoma: Harnessing the Power of Early Detection," OHSUF & DCHF Joint Board Tour, Portland, OR, June 13, 2018

2018 "The War on Melanoma: Melanoma Early Detection in Oregon and Beyond!" Coos Bay Area Hospital, Coos Bay, OR, June 28, 2018

2018 "The War on Melanoma in Oregon: Melanoma Prevention and Detection," Samaritan North Lincoln Hospital, Lincoln City, OR, October 17, 2018

2019 "War on Melanoma: Early Detection in Oregon & Beyond," Mercy Medical Center, Roseburg, OR, February 20, 2019

2019 "War on Melanoma: Early Detection in Oregon & Beyond," Willamette Valley Medical Center, McMinnville, OR, March 15, 2019

2019 "War on Melanoma: Early Detection in Oregon & Beyond," Columbia Memorial Hospital, Astoria, OR, April 17, 2019

2019 "War on Melanoma: Oregon's Early Detection Experiment," Northwest Tribal Clinicians Science Update, Portland, OR, April 24, 2019

2019 "Public Health Campaign: Melanoma Early Detection," Oregon Dermatology Society Meeting, August 10, 2019

2019 "War on Melanoma: Oregon's Early Detection Experiment," Guild Medical Chat, Portland, OR, May 29, 2019

2019 "War On Melanoma: An Oregonian Early Detection Initiative," University of Washington, Seattle, WA, September 4, 2019

2019 "War on Melanoma: Early Detection in Oregon & Beyond," Willamette Dermatology Society, Eugene, OR, October 17, 2019

2020 "Melanoma Detection: Different Tools for Different Populations," Providence Hospital Grand Rounds, Portland OR, January 28, 2020

2020 "Start Seeing Melanoma Now," Central Oregon Community College, Bend, OR, January 22, 2020

2020 "Melanoma detection: Different tools for different populations," OHSU Primary Care Review 2020, Portland, OR, February 5, 2020

2020 "Melanoma detection: Different tools for different populations," OHSU Internal Medicine Review 2020, Portland, OR, March 5, 2020

2020 "SKIN CANCER or A General Introduction to Clinical and Research Topics Relevant to Skin Cancer!" Advanced Cancer Biology Course 2020 OHSU, Portland, OR, May 16, 2020

SERVICE:

Membership in Professional Societies

- American Academy of Dermatology
- American Association for Cancer Research
- American Board of Dermatology
- American Dermatology Association
- American Medical Association
- American Society of Clinical Oncology
- American Society of Human Genetics
- Association of Professors of Dermatology
- Dermatology Foundation
- Medical Dermatology Society
- National Vitiligo Foundation

- Oregon Dermatology Society
- Pacific Dermatologic Association
- Pan American Society for Pigment Cell Research
- Society for Investigative Dermatology
- Society for Melanoma Research
- Southwest Oncology Group
- Utah Medical Association
- Utah Society of Dermatologic Medicine and Surgery

Professional Organization & Scientific Activities

2021 - 2023	Chair, American Academy of Dermatology Melanoma/Skin Cancer Community Programs Committee
2021	Chair, Melanoma/Skin Cancer Community Program Committee, American Academy of Dermatology
2021	Ex-Officio Member, Council on Community, Corporate and Philanthropic Relations, American Academy of Dermatology
2021	Chair, Program Committee for Association of Professors of Dermatology
2020 - present	Director, Montagna Symposium of the Skin
2018 - 2021	Member, Melanoma/Skin Cancer Community Program Committee, American Academy of Dermatology
2015 - present	Board Member, Community Partnership Program, Knight Cancer Institute
2014 - present	Dermatologists Against the Existence of Melanoma (DAMES, Founder)
2013 - present	Member, Oregon Dermatology Society
2013 - 2015	Executive Committee Member, Pacific Dermatologic Association
2011 - present	Safety Monitor, National Institutes of Health, Epidermolysis Bullosa Gene Therapy Clinical Trial run by Peter Marinkovich and Jean Teng
2011 - present	Co-Chair, Southwest Oncology Melanoma Prevention Working Group
2011 - 2012	Chair, Society for Investigative Dermatology, Committee on Education
2009 - 2012	Committee Member, American Society of Clinical Oncology, Education Committee
2007 - present	Member, Pigmented Lesion Subcommittee, subgroup of Melanoma Prevention Working Group

2006 - 2009	Board Member, Pan American Society for Pigment Cell Research
2006 - present	Principle Investigator, Melanoma Tissue Bank Consortium
2006 - 2010	Member, Society for Investigative Dermatology, Translational Task Group

Granting Agency Review Work

2018 - 2019	Grant Reviewer, Melanoma Research Alliance
2018	Grant Reviewer, NIH Program Project Grant
2014 - present	Grant Reviewer, American Skin Association
2011 - present	Project Reviewer, NIAMS DMBA
2011 - 2012	Grant Reviewer, Pfizer
2011 - 2012	Grant Reviewer, FDA
2006 - 2015	Ad Hoc Reviewer, NIH R03, PPG and SPORE
2004	Ad Hoc Reviewer, Veterans Administration Merit Review Grant Program
2004	Ad Hoc Reviewer, Young Investigator Award, Whitehead Institute
1997 - 1998	Ad Hoc Grant Reviewer, Yale National Center of Excellence in Women's Health
1987 - 1989	Ad Hoc Grant Review/Triage Committee, American Heart Association

Editorial and Ad Hoc Review Activities

2000 - 2010	Editor for Melanoma Program Newsletter
2005	Co-editor for Symposium Proceedings, *Journal of Investigative Dermatology*
2010	Editor for *Journal of Investigative Dermatology*, Pachyonychia Congenita Special Volume

Journal Review

- Reviewer for *Annals of Internal Medicine*
- Reviewer for American Academy of Dermatology, *Derm Clips*
- Reviewer for *Archives of Dermatology*
- Reviewer for *Journal of Cutaneous Pathology*
- Reviewer for *Journal of Investigative Dermatology*
- Reviewer for *Journal of Medical Genetics*
- Reviewer for *Journal of the American Academy of Dermatology*

Program Review

2019	External Program Reviewer, Department of Dermatology, Northwestern University Feinberg School of Medicine

Committees – National

2021 - present	UA CP-CTNet Investigators Group
2015 - 2018	Program Chair and Committee Member, Joint Montagna Symposium on the Biology of Skin/PASPCR Annual Meeting, "Melanoma to Vitiligo: The Melanocyte in Biology and Medicine"
2010 - 2013	Pan American Society for Pigment Cell Research, Annual meeting in Salt City, Organizer & Host
2009 - 2011	Make-A-Wish Foundation: Utah Chapter, Educational Outreach Program, Co-Investigator
2005 - 2008	Melanoma Care Coalition, Member
2005 - 2008	Utah Department of Health, Genetics Committee, Medical Advisor
2004 - 2011	Pachyonychia Congenita Project, Medical and Scientific Advisory Board, Chair
2003 - 2012	Pachyonychia Congenita Project, Medical & Scientific Advisory Board, Medical Director & Chairperson
2003 - 2013	GenoMEL, International Melanoma Consortium, Local Principal Investigator
2002 - 2004	Cancer Wellness House, Melanoma/Skin Cancer Awareness Network, Co-Chair
2000 - 2001	SuperGen Inc., Clinical Advisory Board Member
1997 - 1998	Committee Member, Yale School of Medicine, Yale National Center of Excellence in Women's Health, Ad Hoc Grant Reviewer

Committees – University

2021 - present	Health Management Committee, OHSU
2021 - present	Cancer Executive Group, OHSU
2021 - present	Finance Council, OHSU
2020 - present	Practice Plan Management Council, OHSU
2020 - 2021	Knight Cardiovascular Working Group, OHSU
2020 - 2021	White Cap Review Committee, OHSU
2019 - 2021	Funds Flow Committee, OHSU

2019 - 2020	OHSU Brand Architecture Task Force
2018 - present	Cancer Center Support Group, OHSU
2017 - 2018	Department of Biomedical Engineering (BME) Internal Review Committee, OHSU, Member
2014 - 2016	Tech Transfer and Business Development Committee, OHSU, Member
2013 - present	School of Medicine Faculty Council, OHSU
2013 - present	Chair, Melanoma Executive Working Group, OHSU
2013 - present	NCI Cancer Center Support Grant: Cancer Prevention and Control Program, Knight Cancer Institute, OHSU, Member
2013 - present	Collaborative Research Leadership Group (Research Roadmap), OHSU, Member
2007 - 2013	Utah Population Database, Development Committee, University of Utah, Member
2004 - 2007	Huntsman Cancer Institute, Translational Research Committee, University of Utah, Member
2003 - 2006	Eccles Institute of Human Genetics, Advisory Committee, University of Utah, Member
2002 - 2013	Day with a Doctor, Program for Medical Students, Participant
2002	Ladies Home Journal, Health Hero
2000 - 2002	Melanoma Cutaneous Oncology Program, Joint Laboratory Meetings, University of Utah, Director
2000 - 2002	Melanoma Cutaneous Oncology Program, Scientific Journal Club, University of Utah, Director
2000 - 2013	Huntsman Cancer Institute, Familial Melanoma Research Clinic, University of Utah, Director
2000 - 2007	Melanoma Cutaneous Oncology Program, Clinical Database Development Team (CCR), University of Utah, Supervisor
1999 - 2013	Medical Student Research Program, Faculty Mentor
1999 - 2000	Microarray Core Facility, Administration of Users Meeting, Faculty Member
1998 - 2009	Dermatology, Department of Dermatology Research in Progress, University of Utah, Committee Member
1998 - 2008	Dermatology, Resident Selection Committee, Residency Applicants Sub-Committee, University of Utah, Member

1996 - 1997	Dermatology, Yale Dermatology Residents Journal Club, University of Utah, Coordinator

Teaching

2018	Instructor: CELL/CANB 616 –Advanced Topics in Cancer Biology, "Skin Cancer," OHSU
2013 - present	Attending, Medical Dermatology clinic with resident, rotating schedule, 1 resident per quarter, OHSU
2012	Instructor(1): MS2014 SMBJ – Skin Exam/ Recognizing Melanoma/ Sun Block, University of Utah
2011	Instructor(1): MS2013 SMBJ – Dermatology Physical Exam, University of Utah
2011	Instructor(1): MS2013 SMBJ – Dermatology Physical Exam Practice, University of Utah
2008 - 2010	Cutaneous Cancer Syndromes, American Academy of Dermatology
2004 - present	Structure & Function of the Skin-Nails and Pachyonychia Congenita, American Academy of Dermatology
2004 - 2007	To Test or Not to Test: p16 Genetic Testing in Familial Melanoma, American Academy of Dermatology
2001 - 2004	Molecular Biology of Cancer, Cell Cycle Regulation lectures (2), 25-40 students, University of Utah
2000 - 2013	Attending in Resident Clinic, rotating schedule, 2-4 residents, University of Utah
2000 - 2006	Journal clubs, rotating schedule, 1-5 fellows, University of Utah
1999 - 2008	Monthly dermatology lecture, 1-5 medical students or residents, University of Utah

MENTORSHIP: Mentorship roles extending beyond traditional educational activities and supervision include **CDA** (formal mentorship role on a funded career development award); **CS** (Career Sponsor - active promotion of career through regular formal and informal meetings, facilitated networking, and sponsorship of career-promoting activities); **DC** (Dissertation Committee member for PhD); **EP** (Extended Project, greater than a year long with resultant publications); **EUP** (Extended Unpublished Project lasting longer than 1 year); **G** (Grant, serving as a mentor, consultant, or collaborator on a funded grant); **PP** (Published Project requiring substantial oversight and time commitment); **MA** (Masters Thesis Advisor); **SP** (Scholarly Project, formal supervisor of medical school requirement, at least a year-long project); **TG** (Training Grant, formal mentorship role on funded grant).

Year	Name	Undergrad Mentor	Medical School Mentor	Graduate School Mentor	Residency Mentor	Fellowship Mentor	Postdoc Mentor	Faculty Mentor	Current Position

1999-2001	Cheryl Lee Eberting, MD		EUP					C, CS	Founder, AZOVA & Cheryl Lee Eberting Sensitive Skin Care
2000-2002	Neera Agarwal-Antal, MD					PP			Community Dermatologist and Dermatopathologist
2000-2002	Teresa Scholz, MD				PP				Community Dermatologist, Denver, CO
2000-2013	Scott Florell, MD				PP	PP		EP, G, PP, CS	Professor of Dermatology & Dermatopathologist at University of Utah
2001-2003	Nathan Hanson, MD		PP						Community Dermatologist, Logan, UT
2001-2003	Jana Parker, MD		PP						Community Dermatologist, Murray, UT
2002-2004	Brad Whiting, MD		PP						Private Community Provider
2002-2004	Tyler Call, MD		PP						Associate Professor, University of Utah Cancer and Solid Organ Transplants
2002-2004	John Astle, MD, PhD		EUP						Assistant Professor of Pathology, Medical College of Wisconsin
2003-2004	Mark Herron, MD				PP				Community / Pediatric Dermatologist
2003-2009	Ryan Jackson, MD	PP							Assistant Professor, Biochemistry, Utah State University
2003-2013	Mark Eliason, MD					PP		EP, PP, CS	Associate Professor of Dermatology at University of Utah
2003-2005	Adam Karpf, PhD						EP, PP		Professor, University of Nebraska
2003-2010	Christopher Pond, PhD						EP, PP		Research Associate, University of Utah,
2003-2013	Pamela Cassidy, PhD					EP, PP	EP, PP	EP, PP, G, CS	Associate Research Professor, Dermatology, OHSU

2004-2005	**Jason Brinton**	**PP**							**Community Ophthalmologic Surgeon, St. Louis, MO**
2004-2006	**Griffin Jardine, MD**	**EP**							**Pediatric Ophthalmologist, Moran Eye Center, University of Utah**
2004-2007	**Kaylynne Harris, MD**				**PP**				**Deceased**
2004-2009	**Lana Pho, MD**		**PP**		**EP, PP**				**Community Dermatologist in Ogden, UT**
2004-2014	**Anna Luisa Kadekaro, PhD**						**EP, PP**	**EP, PP, CDA**	**Research Assistant Professor, Dermatology, University of Cincinnati**
2004-2021	**April Larson, MD**		**PP**		**EP, PP**			**C, CS**	**Community Dermatologist and Director of Clinical Implementation and Advisory Board at PathologyWatch Digital Pathology**
2005-2011	**Samantha Leaf**			**EP,PP**		**PP**			**Social Psychologist, ISA Group**
2005-2007	**Amber Kostial, MD**	**EUP**							**Community Psychiatrist, Bellingham, Wasthington**
2006-2012	**Jennifer Taber, PhD**			**EP, PP**		**PP**		**PP**	**Assistant Professor, Kent State**
2006-2009	**Murray Cotter, MD**				**PP**				**Mohs Surgeon in Petoskey, Michigan**
2006-2009	**Sally Tran, MD**	**EP, PP**							**Family Medicine, Murray, UT**
2007-2011	**Robyn Hickerson, PhD**						**EP, PP**	**EP, PP, C, CS**	**Acting Principal Investigator, Biological Chemistry and Drug Discovery, University of Dundee, UK**
2007-2013	**Noah Jenkins, PhD**			**EP, PP, DC**					**VP, Innovations, Botanics Innovations, Scientific Advisory**

									Board Member Axxa Global
2008-2010	Chris Koenig, DO	EUP							Emergency Medicine, Mercyhealth Janesville, WI
2008-2011	Stephen Squires, MD		EUP						Community Dermatologist, Evans, GA
2008-2012	Sherri Holmen, PhD							PP, CS	Professor of Surgery & Co-Director of the Melanoma Disease Oriented Research Team; HCI, University of Utah
2009-2013	Pooja Jairam	High School ISEF							Radiology Resident, Brigham & Women's Hospital, Boston, MA
2009-2012	George Samadashwily, MD, PhD				PP		EUP		Returned to home country, Georgia
2005-2013	Robert Andtbacka, MD							PP, CS	Chief Medical Officer at Seven & Eight Biopharmaceuticals
2010-2016	Tawnya Bowles, MD							PP, CS	MD, Intermountain Health Care
2010-2016	Jason Hawkes, MD		PP		PP			CS	Assistant Professor of Dermatology at UC Davis
2011-2020	Annalise Abiodun, MD		CS		CS	CS		CS	Mohs Surgeon & Dermatologist, Mclean, VA
2011-2021	Tammy Stump, PhD			DC, EP, PP		PP, CS		CDA, PP, CS	Research Assistant Professor of Medical Social Sciences, Northwestern Feinberg School of Medicine, Chicago, IL
2014-2017	Kelly Griffith Bauer, MD				EUP, PP				Mohs Surgeon, Seattle, WA
2014-2019	Vessy Korcheva, MD							EUP, PP	Dermatopathologist, Kaiser Permanente, Portland, OR

2014-2021	Yelena Wu, PhD							EP, PP, CS, CDA	Associate Professor of Dermatology, Huntsman Cancer Institute, Utah
2014-2021	Dan Gareau, Ph.D.							EP, G, C	Biomedical Engineer, Rockafeller, NYC & CEO (optics)
2015-2018	Mariah Johnson, MD				EP, PP				Mohs Surgeon, Bend, Oregon
2015-2019	Alla Yarmosh, MD		EUP	MA					Anesthesiology, Portland, OR
2015-2019	Chelsey Kline, PhD						EUP	EUP, CS	Project Science Lead, AbSci Biotechnology, Vancouver WA
2016-2018	Quinn Roth-Carter, Ph.D.			DC					
2016-2021	Olivia Lucero, MD				PP, EP, CS	PP, CS	CS	CS	Mohs Fellow & Research Fellow, OHSU
2016-2021	Tracy Petrie, PhD							EUP, PP, CS	Research faculty, Software Engineer OHSU
2016-2021	Joanne Jeter, MD							PP, CS	Associate Professor Medical Oncology & Genetics, University of Utah
2016-2021	Stephanie Savory, MD							PP, CS	Assistant Professor of Dermatology, UT Southwestern, Dallas, TX
2016-2021	Nathan Rojek, MD				PP	CS		CS	Assistant Professor of Dermatology, University of California Irvine
2017-2021	Kelly Nelson, MD							PP, EUP, CS	Associate Professor of Dermatology, MD Anderson Cancer Center, Houston, TX
2017-2021	Amanda Lund, PhD							EUP, PP, CS	Associate Professor at NYU Langone Health, NY
2017-2021	Terry Medler, PhD					EP, PP, TG	CS, CDA	CS	Postdoctoral fellow Earle A. Chiles Research Institute, Portland, OR

2017-2021	Alison Skalet, MD, PhD							CDA, CS	Associate Professor of Ophthalmology, Director of Ocular Oncology, OHSU
2017-2021	Elizabeth Berry, MD				PP			PP, MA, CS	Assistant Professor of Dermatology, OHSU
2018-2021	Laura Ferris, MD, PhD							PP, CS	Associate Professor and Director of Clinical Trials, Department of Dermatology, University of Pittsburgh
2018-2021	Dale Han, MD							PP, EUP, CS	Assistant Professor of Surgery, Director of Melanoma Clinical Trials, OHSU
2018-2021	Ravi Samatham, PhD						PP	PP, EUP, CS	Instructor of Dermatology, OHSU
2018-2021	Rajan Kulkarni							PP, CS	Associate Professor Of Dermatology, OHSU
2019-2021	Joanna Ludzik, MD, PhD							PP, EUP, CS	Assistant Professor of Dermatology, Co-Director Skin Imaging & Technology Center, OHSU
2019-2021	Alexander Witkowski, MD, PhD							PP, EUP, CS	Assistant Professor of Dermatology, Co-Director Skin Imaging & Technology Center, OHSU
2020-2021	Carter Haag, MD				EUP, G				Resident in Dermatology, OHSU
2021	Caleb Freeman, MD				EUP, CS				Resident in Dermatology, OHSU
2021	Erin Grinich, MD				CS				Resident in Dermatology, OHSU
2021	Smriti Prasad, MD				PP, EUP, CS				Resident in Dermatology, OHSU

2021	**Victoria Orfaly**		**PP, EUP, G, CS**						**OHSU Medical Student**
2021	**Claire Turina**		**PP, EUP, SPA**						**OHSU Medical Student**
2021	**Gina Calco**		**PP, EUP**						**OHSU Medical Student**
2021	**Mary Ryan**		**SP**						**OHSU Medical Student**